"DISEASE.TRAIT"	"risk_count"	"risk_1"	"risk_count_2"	"overall_risk_d * 100"
"1"	"&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels"	4	0	4	100
"2"	"3-month functional outcome in ischaemic stroke (modified Rankin score)"	3	2	1	60
"3"	"Abdominal aortic aneurysm"	1	0	1	100
"4"	"Ability to confide in someone"	1	1	0	50
"5"	"Acne (severe)"	3	1	2	75
"6"	"Activated partial thromboplastin time"	8	4	4	66.6666666666667
"7"	"Acute lymphoblastic leukemia (B-cell precursor)"	2	2	0	50
"8"	"Acute lymphoblastic leukemia (childhood)"	17	11	6	60.7142857142857
"9"	"Acute lymphoblastic leukemia in childhood (B cell precursor)"	1	1	0	50
"10"	"Acylcarnitine levels"	4	2	2	66.6666666666667
"11"	"ADAMTS13 activity"	1	1	0	50
"12"	"Adiponectin levels"	29	16	13	64.4444444444444
"13"	"Adiponectin levels (BMI-adjusted)"	3	1	2	75
"14"	"Adiponectin levels in pregnancy"	2	2	0	50
"15"	"Adiposity"	3	2	1	60
"16"	"Adolescent idiopathic scoliosis"	5	3	2	62.5
"17"	"Adult asthma"	1	0	1	100
"18"	"Adult body size"	44	14	30	75.8620689655173
"19"	"Adult onset asthma or fasting glucose levels"	1	1	0	50
"20"	"Adventurousness"	5	4	1	55.5555555555556
"21"	"Adverse response to chemotherapy (amenorrhea) in breast cancer"	1	1	0	50
"22"	"Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)"	1	1	0	50
"23"	"Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)"	2	2	0	50
"24"	"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)"	1	1	0	50
"25"	"Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)"	2	0	2	100
"26"	"Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)"	1	1	0	50
"27"	"Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)"	2	1	1	66.6666666666667
"28"	"Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)"	1	0	1	100
"29"	"Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)"	1	0	1	100
"30"	"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)"	1	0	1	100
"31"	"Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)"	1	1	0	50
"32"	"Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)"	1	1	0	50
"33"	"Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)"	2	0	2	100
"34"	"Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)"	1	1	0	50
"35"	"Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)"	1	0	1	100
"36"	"Adverse response to drug"	2	2	0	50
"37"	"Age-related cognitive decline (language) (slope of z-scores)"	1	1	0	50
"38"	"Age-related cognitive decline (visuospatial skill) (slope of z-scores)"	1	1	0	50
"39"	"Age-related hearing impairment (high frequency)"	1	1	0	50
"40"	"Age-related macular degeneration"	25	15	10	62.5
"41"	"Age-related macular degeneration (choroidal neovascularisation)"	1	1	0	50
"42"	"Age-related macular degeneration (geographic atrophy)"	1	1	0	50
"43"	"Age-related macular degeneration (MTAG)"	2	0	2	100
"44"	"Age-related nuclear cataracts"	1	1	0	50
"45"	"Age at adiposity rebound"	1	0	1	100
"46"	"Age at first sexual intercourse"	5	2	3	71.4285714285714
"47"	"Age at smoking initiation in chronic obstructive pulmonary disease"	2	0	2	100
"48"	"Age of smoking initiation (MTAG)"	8	5	3	61.5384615384615
"49"	"Aging (time to event)"	2	1	1	66.6666666666667
"50"	"Aging traits (healthspan, parental lifespan or longevity) (multivariate analysis)"	6	4	2	60
"51"	"AIDS"	2	2	0	50
"52"	"AIDS progression"	1	1	0	50
"53"	"Airflow obstruction"	4	4	0	50
"54"	"Airway responsiveness in chronic obstructive pulmonary disease"	1	0	1	100
"55"	"Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)"	2	1	1	66.6666666666667
"56"	"Alanine aminotransferase levels"	21	8	13	72.4137931034483
"57"	"Alanine aminotransferase levels in non-alcoholic fatty liver disease"	1	1	0	50
"58"	"Albuminuria"	1	1	0	50
"59"	"Alcohol and nicotine co-dependence"	2	2	0	50
"60"	"Alcohol consumption"	11	8	3	57.8947368421053
"61"	"Alcohol consumption (drinkers vs non-drinkers)"	1	1	0	50
"62"	"Alcohol consumption (drinks per week)"	21	15	6	58.3333333333333
"63"	"Alcohol consumption (drinks per week) (MTAG)"	16	10	6	61.5384615384615
"64"	"Alcohol consumption (heavy vs. light/non-drinkers)"	1	0	1	100
"65"	"Alcohol consumption (max-drinks)"	1	0	1	100
"66"	"Alcohol consumption (transferrin glycosylation)"	3	3	0	50
"67"	"Alcohol consumption in current drinkers"	1	1	0	50
"68"	"Alcohol dependence"	9	4	5	69.2307692307692
"69"	"Alcohol dependence (age at onset)"	5	2	3	71.4285714285714
"70"	"Alcohol dependence symptom count"	1	0	1	100
"71"	"Alcohol use disorder"	3	1	2	75
"72"	"Alcohol use disorder (consumption score)"	5	2	3	71.4285714285714
"73"	"Alcohol use disorder (dependence and problematic use scores)"	1	1	0	50
"74"	"Alcohol use disorder (total score)"	3	2	1	60
"75"	"Alcoholism (12-month weekly alcohol consumption)"	1	1	0	50
"76"	"Alcoholism (alcohol dependence factor score)"	3	0	3	100
"77"	"Alcoholism (alcohol use disorder factor score)"	3	0	3	100
"78"	"Alcoholism (heaviness of drinking)"	1	1	0	50
"79"	"Allergic disease (asthma, hay fever and/or eczema) (age of onset)"	6	5	1	54.5454545454545
"80"	"Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)"	7	6	1	53.8461538461539
"81"	"Allergic disease (asthma, hay fever or eczema)"	26	14	12	65
"82"	"Allergic rhinitis"	4	4	0	50
"83"	"Allergic sensitization"	11	5	6	68.75
"84"	"Alopecia areata"	7	6	1	53.8461538461539
"85"	"Alzheimer's disease"	19	9	10	67.8571428571429
"86"	"Alzheimer's disease (late onset)"	26	15	11	63.4146341463415
"87"	"Alzheimer's disease (onset at age over 80)"	1	1	0	50
"88"	"Alzheimer's disease (onset between ages 58 and 79)"	5	4	1	55.5555555555556
"89"	"Alzheimer's disease biomarkers"	2	2	0	50
"90"	"Alzheimer's disease in APOE e4- carriers"	6	3	3	66.6666666666667
"91"	"Alzheimer's disease in APOE e4+ carriers"	5	3	2	62.5
"92"	"Alzheimer's disease or family history of Alzheimer's disease"	12	9	3	57.1428571428571
"93"	"Alzheimer disease and age of onset"	8	2	6	80
"94"	"Amino acid levels"	2	0	2	100
"95"	"Amyloid A serum levels"	1	1	0	50
"96"	"Amyotrophic lateral sclerosis"	11	8	3	57.8947368421053
"97"	"Amyotrophic lateral sclerosis (age of onset)"	1	1	0	50
"98"	"Androgen levels"	1	0	1	100
"99"	"Angiopoietin-1 receptor levels"	2	2	0	50
"100"	"Ankle injury"	1	1	0	50
"101"	"Ankylosing spondylitis"	37	26	11	58.7301587301587
"102"	"Anorexia nervosa"	6	2	4	75
"103"	"Anthracycline-induced cardiotoxicity in childhood cancer"	2	2	0	50
"104"	"Anthropometric traits"	3	3	0	50
"105"	"Anthropometric traits in newborns"	4	4	0	50
"106"	"Anti-herpes simplex virus 6 IE1A IgG seropositivity"	1	0	1	100
"107"	"Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis"	4	2	2	66.6666666666667
"108"	"Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis"	2	0	2	100
"109"	"Antibody level in response to infection"	1	1	0	50
"110"	"Anticoagulant levels"	1	1	0	50
"111"	"Antineutrophil cytoplasmic antibody-associated vasculitis"	1	1	0	50
"112"	"Antipsychotic drug-induced QTc interval change in schizophrenia"	2	1	1	66.6666666666667
"113"	"antipsychotic drug dosage in schizophrenia or schizoaffective disorder"	1	1	0	50
"114"	"Antisaccade task score"	1	1	0	50
"115"	"Anxiety and major depressive disorder"	1	1	0	50
"116"	"Anxiety disorder"	1	1	0	50
"117"	"Anxiety/tension (special factor of neuroticism)"	2	2	0	50
"118"	"Aortic-valve calcification"	1	1	0	50
"119"	"Aortic root size"	3	3	0	50
"120"	"Aortic valve stenosis"	2	2	0	50
"121"	"Apolipoprotein A1 levels"	47	18	29	72.3076923076923
"122"	"Apolipoprotein B levels"	46	17	29	73.015873015873
"123"	"Apolipoprotein Levels"	3	3	0	50
"124"	"Appendicular lean mass"	75	36	39	67.5675675675676
"125"	"AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor"	1	0	1	100
"126"	"Arterial stiffness index"	1	0	1	100
"127"	"Arthritis (juvenile idiopathic)"	4	2	2	66.6666666666667
"128"	"Aseptic loosening in total joint arthroplasty"	1	1	0	50
"129"	"Aspartate aminotransferase levels"	18	11	7	62.0689655172414
"130"	"Aspirin exacerbated respiratory disease in asthmatics"	1	1	0	50
"131"	"Aspirin hydrolysis (plasma)"	1	1	0	50
"132"	"Asthma"	113	54	59	67.6646706586826
"133"	"Asthma (adult onset)"	4	3	1	57.1428571428571
"134"	"Asthma (age of onset)"	6	4	2	60
"135"	"Asthma (bronchodilator response)"	2	1	1	66.6666666666667
"136"	"Asthma (childhood onset)"	13	7	6	65
"137"	"Asthma (moderate or severe)"	3	1	2	75
"138"	"Asthma (time to childhood onset) x early life tobacco smoke interaction"	2	2	0	50
"139"	"Asthma (time to onset)"	2	1	1	66.6666666666667
"140"	"Asthma and hay fever"	6	2	4	75
"141"	"Asthma exacerbations in inhaled corticosteroid treatment"	3	1	2	75
"142"	"Asthma onset (childhood vs adult)"	8	6	2	57.1428571428571
"143"	"Atopic dermatitis"	17	10	7	62.962962962963
"144"	"Atrial fibrillation"	60	19	41	75.9493670886076
"145"	"Atrial fibrillation/atrial flutter"	1	0	1	100
"146"	"Atrioventricular conduction"	2	2	0	50
"147"	"Attention deficit hyperactivity disorder"	3	2	1	60
"148"	"Attention deficit hyperactivity disorder (childhood)"	2	1	1	66.6666666666667
"149"	"Attention deficit hyperactivity disorder (combined symptoms)"	2	2	0	50
"150"	"Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)"	4	2	2	66.6666666666667
"151"	"Attention deficit hyperactivity disorder (inattention symptoms)"	2	2	0	50
"152"	"Attention deficit hyperactivity disorder (time to onset)"	3	2	1	60
"153"	"Attention deficit hyperactivity disorder and conduct disorder"	7	4	3	63.6363636363636
"154"	"Attention deficit hyperactivity disorder or cannabis use"	5	4	1	55.5555555555556
"155"	"Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)"	1	1	0	50
"156"	"Attention function in attention deficit hyperactive disorder"	4	2	2	66.6666666666667
"157"	"Atypical femoral fracture in phosphonate treatment"	1	1	0	50
"158"	"Autism"	1	1	0	50
"159"	"Autism and educational attainment (MTAG)"	1	0	1	100
"160"	"Autism and major depressive disorder (MTAG)"	1	1	0	50
"161"	"Autism spectrum disorder"	4	2	2	66.6666666666667
"162"	"Autism spectrum disorder or schizophrenia"	19	12	7	61.2903225806452
"163"	"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)"	18	10	8	64.2857142857143
"164"	"Autoimmune thyroid disease"	15	10	5	60
"165"	"Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)"	1	1	0	50
"166"	"Autoimmune traits"	1	1	0	50
"167"	"Autoimmune traits (pleiotropy)"	5	3	2	62.5
"168"	"Automobile speeding propensity"	1	0	1	100
"169"	"Axial length"	1	0	1	100
"170"	"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)"	3	1	2	75
"171"	"B cell acute lymphoblastic leukaemia (hyperdiploid negative)"	1	1	0	50
"172"	"B cell acute lymphoblastic leukaemia (normal cytogenetics)"	1	1	0	50
"173"	"B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative)"	1	1	0	50
"174"	"B cell non-Hodgkin lymphoma"	1	1	0	50
"175"	"Barrett's esophagus"	3	1	2	75
"176"	"Barrett's esophagus  or Esophageal adenocarcinoma"	1	0	1	100
"177"	"Basal cell carcinoma"	35	19	16	64.8148148148148
"178"	"Basophil count"	31	18	13	63.265306122449
"179"	"Basophil percentage of granulocytes"	5	4	1	55.5555555555556
"180"	"Basophil percentage of white cells"	14	6	8	70
"181"	"Behcet's disease"	3	2	1	60
"182"	"Benign prostatic hyperplasia and lower urinary tract symptoms"	2	1	1	66.6666666666667
"183"	"Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)"	1	0	1	100
"184"	"Beta-2 microglubulin plasma levels"	3	2	1	60
"185"	"Betaine levels in individuals undergoing cardiac evaluation"	1	0	1	100
"186"	"Bilirubin levels"	8	8	0	50
"187"	"Binge eating behaviour and bipolar disorder"	1	1	0	50
"188"	"Bioavailable testosterone levels"	39	14	25	73.5849056603774
"189"	"Biochemical measures"	3	1	2	75
"190"	"Biomedical quantitative traits"	4	3	1	57.1428571428571
"191"	"Bipolar disorder"	33	22	11	60
"192"	"Bipolar disorder and schizophrenia"	2	1	1	66.6666666666667
"193"	"Bipolar disorder lithium response (categorical) or schizophrenia"	1	0	1	100
"194"	"Bipolar disorder lithium response (continuous) or schizophrenia"	1	0	1	100
"195"	"Bipolar disorder or attention deficit hyperactivity disorder"	1	0	1	100
"196"	"Bipolar disorder or body mass index"	3	2	1	60
"197"	"Bipolar disorder or major depressive disorder"	6	4	2	60
"198"	"Bipolar disorder with mood-incongruent psychosis"	1	0	1	100
"199"	"Bipolar I disorder"	6	4	2	60
"200"	"Birth length"	2	2	0	50
"201"	"Birth length (MTAG)"	7	5	2	58.3333333333333
"202"	"Birth weight"	53	33	20	61.6279069767442
"203"	"Birth weight (MTAG)"	10	6	4	62.5
"204"	"Bisphosphonate-associated atypical femoral fracture"	2	2	0	50
"205"	"Bitter alcoholic beverage consumption"	10	5	5	66.6666666666667
"206"	"Bitter beverage consumption"	5	2	3	71.4285714285714
"207"	"Bitter non-alcoholic beverage consumption"	3	2	1	60
"208"	"Bitter taste perception (6-n-propylthiouracil) in obesity with metabolic syndrome"	2	2	0	50
"209"	"Bitter taste perception (phenylthiocarbamide) in obesity with metabolic syndrome"	2	2	0	50
"210"	"BK polyomavirus VP1 antibody levels"	1	1	0	50
"211"	"Black vs. blond hair color"	4	2	2	66.6666666666667
"212"	"Black vs. red hair color"	3	2	1	60
"213"	"Bladder cancer"	18	7	11	72
"214"	"Blond vs. brown hair color"	2	2	0	50
"215"	"Blond vs. brown/black hair color"	8	5	3	61.5384615384615
"216"	"Blood and toenail selenium levels"	8	7	1	53.3333333333333
"217"	"Blood glucose levels"	3	1	2	75
"218"	"Blood metabolite levels"	152	83	69	64.6808510638298
"219"	"Blood metabolite ratios"	32	21	11	60.377358490566
"220"	"Blood osmolality (transformed sodium)"	3	1	2	75
"221"	"Blood pressure"	39	26	13	60
"222"	"Blood pressure (age interaction)"	2	2	0	50
"223"	"Blood pressure measurement (cold pressor test)"	3	3	0	50
"224"	"Blood pressure measurement (high sodium and potassium intervention)"	2	2	0	50
"225"	"Blood protein levels"	426	252	174	62.8318584070797
"226"	"Blood protein levels in cardiovascular risk"	13	6	7	68.4210526315789
"227"	"Blood trace element (Se levels)"	1	1	0	50
"228"	"Blood urea nitrogen levels"	17	10	7	62.962962962963
"229"	"Blue vs. green eyes"	1	1	0	50
"230"	"BMI (adjusted for smoking behaviour)"	100	54	46	64.9350649350649
"231"	"BMI at adiposity rebound"	1	1	0	50
"232"	"BMI in non-smokers"	75	39	36	65.7894736842105
"233"	"BMI in smokers"	24	13	11	64.8648648648649
"234"	"Body fat distribution (arm fat ratio)"	12	6	6	66.6666666666667
"235"	"Body fat distribution (leg fat ratio)"	22	18	4	55
"236"	"Body fat distribution (trunk fat ratio)"	23	17	6	57.5
"237"	"Body fat mass"	1	0	1	100
"238"	"Body fat percentage"	16	8	8	66.6666666666667
"239"	"Body mass (lean)"	1	0	1	100
"240"	"Body mass in chronic obstructive pulmonary disease"	1	0	1	100
"241"	"Body mass index"	881	523	358	62.7492877492878
"242"	"Body mass index (adult)"	15	11	4	57.6923076923077
"243"	"Body mass index (age <50)"	5	2	3	71.4285714285714
"244"	"Body mass index (age interaction)"	2	1	1	66.6666666666667
"245"	"Body mass index (age>50)"	4	2	2	66.6666666666667
"246"	"Body mass index (ever vs never smoking interaction)"	1	1	0	50
"247"	"Body mass index (joint analysis main effects and smoking interaction)"	95	52	43	64.6258503401361
"248"	"Body mass index (SNP x SNP interaction)"	5	2	3	71.4285714285714
"249"	"Body mass index in asthmatics"	1	1	0	50
"250"	"Body mass index in physically active individuals"	63	43	20	59.4339622641509
"251"	"Body mass index in physically inactive individuals"	26	20	6	56.5217391304348
"252"	"Body mass index x age interaction"	4	2	2	66.6666666666667
"253"	"Body mass index x sex x age interaction (4df test)"	6	2	4	75
"254"	"Body size at age 10"	38	20	18	65.5172413793103
"255"	"Bone mineral content"	5	5	0	50
"256"	"Bone mineral density"	17	15	2	53.125
"257"	"Bone mineral density (hip)"	19	16	3	54.2857142857143
"258"	"Bone mineral density (hip) and age at menarche"	1	1	0	50
"259"	"Bone mineral density (hip) and hip bone size"	3	0	3	100
"260"	"Bone mineral density (paediatric, lower limb)"	9	5	4	64.2857142857143
"261"	"Bone mineral density (paediatric, skull)"	11	5	6	68.75
"262"	"Bone mineral density (paediatric, total body less head)"	11	8	3	57.8947368421053
"263"	"Bone mineral density (paediatric, upper limb)"	8	4	4	66.6666666666667
"264"	"Bone mineral density (spine)"	23	16	7	58.974358974359
"265"	"Bone mineral density (total hip)"	1	1	0	50
"266"	"Bone properties (heel)"	10	6	4	62.5
"267"	"Bone ultrasound measurement (broadband ultrasound attenuation)"	1	1	0	50
"268"	"Bone ultrasound measurement (velocity of sound)"	3	3	0	50
"269"	"Borderline personality disorder"	2	1	1	66.6666666666667
"270"	"Brain structure"	1	1	0	50
"271"	"Brain structure (hippocampal volume)"	3	3	0	50
"272"	"Brain structure (temporal lobe volume)"	2	0	2	100
"273"	"Brain volume in infants (white matter)"	1	0	1	100
"274"	"Brainstem volume"	1	1	0	50
"275"	"Branched-chain amino acid levels (Leucine)"	1	1	0	50
"276"	"Branched-chain amino acid levels (Valine)"	1	1	0	50
"277"	"BRCA1/2-negative high-risk breast cancer"	3	0	3	100
"278"	"Breast cancer"	284	138	146	67.2985781990521
"279"	"Breast cancer (estrogen-receptor negative)"	24	12	12	66.6666666666667
"280"	"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)"	1	0	1	100
"281"	"Breast cancer (estrogen-receptor positive)"	1	0	1	100
"282"	"Breast cancer (survival)"	3	0	3	100
"283"	"Breast Cancer in BRCA1 mutation carriers"	5	1	4	83.3333333333333
"284"	"Breast cancer in BRCA2 mutation carriers"	1	1	0	50
"285"	"Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy"	1	0	1	100
"286"	"Breast milk fatty acid composition (infant genotype effect)"	2	1	1	66.6666666666667
"287"	"Breast milk fatty acid composition (maternal genotype effect)"	3	1	2	75
"288"	"Breast size"	6	6	0	50
"289"	"Broad depression or bipolar disorder"	1	0	1	100
"290"	"Broad depression or major depressive disorder (self-reported)"	1	0	1	100
"291"	"Broad depression or schizophrenia"	5	3	2	62.5
"292"	"Bronchopulmonary dysplasia"	1	1	0	50
"293"	"Bronchopulmonary dysplasia in preterm infants"	1	1	0	50
"294"	"Brown vs. black hair color"	3	3	0	50
"295"	"Brugada syndrome"	1	1	0	50
"296"	"Bulimia nervosa"	2	1	1	66.6666666666667
"297"	"Butyrylcholinesterase levels"	2	2	0	50
"298"	"C-C motif chemokine 20 levels"	1	0	1	100
"299"	"C-C motif chemokine 3 levels"	1	1	0	50
"300"	"C-peptide levels in type I diabetes"	1	1	0	50
"301"	"C-reactive protein"	11	5	6	68.75
"302"	"C-reactive protein and white blood cell count"	4	1	3	80
"303"	"C-reactive protein levels"	115	41	74	73.7179487179487
"304"	"C-reactive protein levels or HDL-cholesterol levels (pleiotropy)"	9	4	5	69.2307692307692
"305"	"C-reactive protein levels or LDL-cholesterol levels (pleiotropy)"	4	2	2	66.6666666666667
"306"	"C-reactive protein levels or total cholesterol levels (pleiotropy)"	6	1	5	85.7142857142857
"307"	"C-reactive protein levels or triglyceride levels (pleiotropy)"	8	5	3	61.5384615384615
"308"	"C-X-C motif chemokine 6 levels"	1	1	0	50
"309"	"Caffeine consumption"	3	2	1	60
"310"	"Caffeine consumption from coffee"	6	4	2	60
"311"	"Caffeine consumption from coffee or tea"	6	4	2	60
"312"	"Caffeine consumption from tea"	3	2	1	60
"313"	"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)"	2	2	0	50
"314"	"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)"	4	4	0	50
"315"	"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)"	4	4	0	50
"316"	"Calcific aortic valve stenosis"	1	1	0	50
"317"	"Calcium levels"	8	5	3	61.5384615384615
"318"	"Cancer"	2	1	1	66.6666666666667
"319"	"Cancer (pleiotropy)"	15	7	8	68.1818181818182
"320"	"Cancer (pleiotropy)(bidirectional)"	3	1	2	75
"321"	"Cannabis dependence symptom count"	2	0	2	100
"322"	"Cannabis use (age at onset)"	1	1	0	50
"323"	"Cannabis use (initiation)"	3	2	1	60
"324"	"Cardiac structure and function"	1	1	0	50
"325"	"Cardiac Troponin-T levels"	2	1	1	66.6666666666667
"326"	"Cardiovascular disease risk factors"	4	4	0	50
"327"	"Cardiovascular heart disease in diabetics"	1	0	1	100
"328"	"Cardiovascular risk factors (age interaction)"	1	0	1	100
"329"	"Carotenoid and tocopherol levels"	1	0	1	100
"330"	"Carotid intima media thickness"	3	3	0	50
"331"	"Carotid intima media thickness (mean-maximum)"	1	0	1	100
"332"	"Carotid intima media thickness x smoking interaction"	3	1	2	75
"333"	"Carotid plaque"	1	0	1	100
"334"	"Carotid plaque burden"	1	1	0	50
"335"	"Carotid plaques in rheumatoid arthritis"	1	0	1	100
"336"	"Carpal tunnel syndrome"	1	1	0	50
"337"	"Cathepsin D levels"	2	2	0	50
"338"	"Cathepsin L1 levels"	2	2	0	50
"339"	"Caudate nucleus volume"	3	1	2	75
"340"	"CCL19 levels"	1	1	0	50
"341"	"CCL25 levels"	1	1	0	50
"342"	"Celiac disease"	11	8	3	57.8947368421053
"343"	"Celiac disease or Rheumatoid arthritis"	4	3	1	57.1428571428571
"344"	"Central corneal thickness"	12	5	7	70.5882352941176
"345"	"Central retinal vein equivalent"	1	1	0	50
"346"	"Ceramide levels"	1	1	0	50
"347"	"Cerebral amyloid angiopathy"	1	0	1	100
"348"	"Cerebral amyloid deposition (PET imaging)"	8	5	3	61.5384615384615
"349"	"Cerebrospinal fluid AB1-42 levels"	4	2	2	66.6666666666667
"350"	"Cerebrospinal fluid biomarker levels"	1	0	1	100
"351"	"Cerebrospinal fluid levels of Alzheimer's disease-related proteins"	3	1	2	75
"352"	"Cerebrospinal fluid t-tau:AB1-42 ratio"	1	0	1	100
"353"	"Cerebrospinal P-tau181p levels"	1	1	0	50
"354"	"Cerebrospinal T-tau levels"	4	2	2	66.6666666666667
"355"	"Cerivastatin-induced rhabdomyolysis"	1	0	1	100
"356"	"Cervical artery dissection"	3	3	0	50
"357"	"Cervical cancer"	5	3	2	62.5
"358"	"Change in glucose in response to thiazide diuretic treatment in hypertension"	1	1	0	50
"359"	"Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)"	1	1	0	50
"360"	"Childhood and early adolescence aggressive behavior"	1	0	1	100
"361"	"Childhood body mass index"	23	16	7	58.974358974359
"362"	"Childhood obesity"	2	2	0	50
"363"	"Childhood onset ulcerative colitis"	1	1	0	50
"364"	"Childhood steroid-sensitive nephrotic syndrome"	1	1	0	50
"365"	"Chitinase-3-like protein 1 levels"	1	1	0	50
"366"	"Chlamydia trachomatis PorB antibody levels"	1	0	1	100
"367"	"Cholesterol"	4	3	1	57.1428571428571
"368"	"Cholesterol efflux capacity"	2	1	1	66.6666666666667
"369"	"Cholesterol efflux capacity (ABCA-1 dependent assay)"	1	1	0	50
"370"	"Cholesterol efflux capacity (BHK stimulated assay)"	1	1	0	50
"371"	"Cholesterol efflux capacity (cAMP stimulated assay)"	2	1	1	66.6666666666667
"372"	"Cholesterol, total"	80	61	19	56.7375886524823
"373"	"Cholesteryl ester levels"	3	3	0	50
"374"	"Cholesteryl ester transfer protein levels"	2	1	1	66.6666666666667
"375"	"Chronic bronchitis and chronic obstructive pulmonary disease"	3	3	0	50
"376"	"Chronic hepatitis B infection"	8	7	1	53.3333333333333
"377"	"Chronic hepatitis C infection"	1	1	0	50
"378"	"Chronic kidney disease"	22	12	10	64.7058823529412
"379"	"Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes"	1	1	0	50
"380"	"Chronic lymphocytic leukemia"	38	22	16	63.3333333333333
"381"	"Chronic mucus hypersecretion"	1	0	1	100
"382"	"Chronic myeloid leukemia"	1	1	0	50
"383"	"Chronic obstructive pulmonary disease"	20	10	10	66.6666666666667
"384"	"Chronic obstructive pulmonary disease-related biomarkers"	12	10	2	54.5454545454545
"385"	"Chronic obstructive pulmonary disease (moderate to severe)"	4	3	1	57.1428571428571
"386"	"Chronic obstructive pulmonary disease (severe)"	6	4	2	60
"387"	"Chronic rhinosinusitis"	1	1	0	50
"388"	"Chronic rhinosinusitis with nasal polyps"	1	1	0	50
"389"	"Chronotype"	34	19	15	64.1509433962264
"390"	"Chronotype (sMEQ score)"	1	0	1	100
"391"	"Cigarettes smoked per day (MTAG)"	8	6	2	57.1428571428571
"392"	"Circulating cell-free DNA"	1	1	0	50
"393"	"Circulating fibroblast growth factor 23 levels"	1	1	0	50
"394"	"circulating leptin levels"	44	8	36	84.6153846153846
"395"	"circulating leptin levels adjusted for BMI"	46	15	31	75.4098360655738
"396"	"Circulating myeloperoxidase levels (plasma)"	1	1	0	50
"397"	"Circulating myeloperoxidase levels (serum)"	3	2	1	60
"398"	"Cirrhosis (alcohol related)"	1	1	0	50
"399"	"Cisplatin-induced ototoxicity"	3	2	1	60
"400"	"Classic bladder exstrophy"	1	1	0	50
"401"	"Cleft lip"	1	1	0	50
"402"	"Cleft palate"	4	4	0	50
"403"	"Clozapine-induced agranulocytosis"	2	2	0	50
"404"	"Clozapine concentration in schizophrenia"	1	1	0	50
"405"	"Coffee consumption"	16	11	5	59.2592592592593
"406"	"Coffee consumption (cups per day)"	8	5	3	61.5384615384615
"407"	"Cognitive aspects of educational attainment"	23	6	17	79.3103448275862
"408"	"Cognitive decline rate in late mild cognitive impairment"	14	0	14	100
"409"	"Cognitive empathy"	4	0	4	100
"410"	"Cognitive performance"	15	7	8	68.1818181818182
"411"	"Cognitive performance (MTAG)"	31	15	16	67.3913043478261
"412"	"Cold sores"	1	1	0	50
"413"	"Colon cancer"	2	1	1	66.6666666666667
"414"	"Colorectal cancer"	130	85	45	60.4651162790698
"415"	"Colorectal cancer or advanced adenoma"	18	12	6	60
"416"	"Colorectal or endometrial cancer"	2	1	1	66.6666666666667
"417"	"Common carotid intima-media thickness"	1	1	0	50
"418"	"Common carotid intima-media thickness in HIV negative individuals"	1	0	1	100
"419"	"Common traits (Other)"	2	1	1	66.6666666666667
"420"	"Complement C3 and C4 levels"	4	2	2	66.6666666666667
"421"	"Composite immunoglobulin trait (IgA/IgG)"	1	1	0	50
"422"	"Comprehensive strength and appendicular lean mass"	2	2	0	50
"423"	"Conduct disorder"	1	0	1	100
"424"	"Conduct disorder (maternal expressed emotions interaction)"	3	2	1	60
"425"	"Conscientiousness"	1	1	0	50
"426"	"Corneal astigmatism"	8	0	8	100
"427"	"Corneal curvature"	14	10	4	58.3333333333333
"428"	"Corneal structure"	15	8	7	65.2173913043478
"429"	"Coronary artery calcification"	4	4	0	50
"430"	"Coronary artery disease"	130	74	56	63.7254901960784
"431"	"Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)"	20	12	8	62.5
"432"	"Coronary artery disease and LDL cholesterol levels (multivariate analysis)"	1	1	0	50
"433"	"Coronary artery disease and total cholesterol levels (multivariate analysis)"	1	0	1	100
"434"	"Coronary artery disease or ischemic stroke"	1	1	0	50
"435"	"Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)"	1	0	1	100
"436"	"Coronary heart disease"	39	20	19	66.1016949152542
"437"	"Cortical surface area"	16	4	12	80
"438"	"Cortical thickness"	2	1	1	66.6666666666667
"439"	"Cortisol levels (saliva)"	1	0	1	100
"440"	"Cotinine glucuronidation"	5	0	5	100
"441"	"COVID-19 (critical illness vs population)"	1	1	0	50
"442"	"Craniofacial microsomia"	5	2	3	71.4285714285714
"443"	"Creatinine levels"	8	5	3	61.5384615384615
"444"	"Creativity"	1	0	1	100
"445"	"Creutzfeldt-Jakob disease (sporadic)"	2	1	1	66.6666666666667
"446"	"Crohn's disease"	134	77	57	63.5071090047393
"447"	"Crohn's disease-related phenotypes"	3	2	1	60
"448"	"Crohn's disease (indolent vs progressive)"	1	1	0	50
"449"	"Crohn's disease and celiac disease"	1	1	0	50
"450"	"Crohn's disease or systemic sclerosis"	1	1	0	50
"451"	"CTACK levels"	2	0	2	100
"452"	"Cutaneous lupus erythematosus"	1	1	0	50
"453"	"Cutaneous malignant melanoma"	7	5	2	58.3333333333333
"454"	"Cutaneous melanoma or hair colour"	4	0	4	100
"455"	"Cutaneous psoriasis"	3	2	1	60
"456"	"Cutaneous squamous cell carcinoma"	5	5	0	50
"457"	"Cystic fibrosis-related diabetes"	1	0	1	100
"458"	"Cystic fibrosis severity"	1	0	1	100
"459"	"D-dimer levels"	3	2	1	60
"460"	"Daytime nap"	1	1	0	50
"461"	"Daytime sleep phenotypes"	1	0	1	100
"462"	"Decreased sensory function in Charcot-Marie-Tooth disease type 1A"	1	0	1	100
"463"	"Deep white matter hyperintensities"	1	0	1	100
"464"	"Dehydroepiandrosterone sulphate levels"	5	5	0	50
"465"	"Deliberate self-harm"	2	0	2	100
"466"	"Delta-6 desaturase activity"	3	3	0	50
"467"	"Dementia and core Alzheimer's disease neuropathologic changes"	2	2	0	50
"468"	"Dementia with Lewy bodies"	1	0	1	100
"469"	"Dentate gyrus granule cell layer volume"	1	1	0	50
"470"	"Dentures"	4	3	1	57.1428571428571
"471"	"Depressed affect"	3	2	1	60
"472"	"Depression"	12	8	4	60
"473"	"Depression (broad)"	2	1	1	66.6666666666667
"474"	"Depression (quantitative trait)"	6	4	2	60
"475"	"Depression in response to interferon-based therapy in chronic hepatitis C"	1	1	0	50
"476"	"Depressive symptoms"	8	4	4	66.6666666666667
"477"	"Depressive symptoms (MTAG)"	3	3	0	50
"478"	"Depressive symptoms (SSRI exposure interaction)"	1	1	0	50
"479"	"Dermatomyositis"	1	1	0	50
"480"	"Developmental dysplasia of the hip"	3	3	0	50
"481"	"Developmental language disorder"	1	1	0	50
"482"	"Developmental language disorder (linguistic errors)"	2	0	2	100
"483"	"Diabetes (gestational)"	2	2	0	50
"484"	"Diabetic retinopathy"	8	4	4	66.6666666666667
"485"	"Diabetic retinopathy in type 2 diabetes"	1	0	1	100
"486"	"Diacylglyceride levels"	2	0	2	100
"487"	"Diastolic blood pressure"	181	105	76	63.2867132867133
"488"	"Diastolic blood pressure (alcohol consumption interaction)"	1	1	0	50
"489"	"Diastolic blood pressure (long-term average)"	1	0	1	100
"490"	"Diastolic blood pressure night-to-day ratio in hypertension"	1	1	0	50
"491"	"Diastolic blood pressure response to hydrochlorothiazide in hypertension"	1	0	1	100
"492"	"Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)"	5	1	4	83.3333333333333
"493"	"Diastolic blood pressure x alcohol consumption interaction (2df test)"	5	4	1	55.5555555555556
"494"	"Diastolic blood pressure x quantitative lifestyle risk score interaction (1df test)"	1	1	0	50
"495"	"Diastolic blood pressure x quantitative lifestyle risk score interaction (2df test)"	1	1	0	50
"496"	"Diastolic blood pressure x sodium interaction (1df test)"	1	1	0	50
"497"	"Dickkopf-related protein 1 levels"	1	1	0	50
"498"	"Dietary macronutrient intake"	13	6	7	68.4210526315789
"499"	"Diffuse plaques"	1	0	1	100
"500"	"Diffusing capacity of carbon monoxide"	3	2	1	60
"501"	"Diffusing capacity of the lung for carbon monoxide traits"	1	0	1	100
"502"	"Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)"	1	1	0	50
"503"	"Digit length ratio"	3	2	1	60
"504"	"Digit length ratio (left hand)"	6	4	2	60
"505"	"Digit length ratio (right hand)"	3	2	1	60
"506"	"Diisocyanate-induced asthma"	3	3	0	50
"507"	"Disc degeneration (lumbar)"	4	3	1	57.1428571428571
"508"	"Disease progression in age-related macular degeneration"	1	0	1	100
"509"	"Disease progression in age-related macular degeneration (adjusted for baseline)"	1	1	0	50
"510"	"Diverticular disease"	2	1	1	66.6666666666667
"511"	"Diverticulitis"	1	0	1	100
"512"	"DNA methylation (parent-of-origin)"	5	0	5	100
"513"	"DNA methylation (variation)"	2	1	1	66.6666666666667
"514"	"Drinking behavior"	1	0	1	100
"515"	"Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)"	4	1	3	80
"516"	"Duodenal ulcer"	1	1	0	50
"517"	"Dupuytren's disease"	4	3	1	57.1428571428571
"518"	"E-selectin levels"	3	3	0	50
"519"	"Ear morphology"	1	1	0	50
"520"	"Early age-related macular degeneration"	2	2	0	50
"521"	"Early cardiac repolarization"	2	2	0	50
"522"	"Early childhood aggressive behavior"	1	1	0	50
"523"	"Early onset atrial fibrillation"	1	0	1	100
"524"	"Ease of getting up in the morning"	3	2	1	60
"525"	"Eating disorders"	3	0	3	100
"526"	"Eating disorders (purging via substances)"	2	0	2	100
"527"	"Economic and political preferences"	6	3	3	66.6666666666667
"528"	"Economic and political preferences (environmentalism)"	8	6	2	57.1428571428571
"529"	"Economic and political preferences (fairness)"	3	2	1	60
"530"	"Economic and political preferences (feminism/equality)"	4	2	2	66.6666666666667
"531"	"Economic and political preferences (immigration/crime)"	4	2	2	66.6666666666667
"532"	"Economic and political preferences (time)"	2	0	2	100
"533"	"Educational attainment"	7	5	2	58.3333333333333
"534"	"Educational attainment (MTAG)"	61	33	28	64.8936170212766
"535"	"Educational attainment (years of education)"	71	37	34	65.7407407407407
"536"	"Electrocardiogram morphology (amplitude at temporal datapoints)"	726	299	427	70.8292682926829
"537"	"Electrocardiographic conduction measures"	6	3	3	66.6666666666667
"538"	"Electrocardiographic traits"	8	3	5	72.7272727272727
"539"	"Electroencephalographic traits in alcoholism"	2	1	1	66.6666666666667
"540"	"Emphysema-related traits"	1	0	1	100
"541"	"Emphysema annual change measurement in smokers (adjusted lung density)"	2	1	1	66.6666666666667
"542"	"Emphysema annual change measurement in smokers (percent low attenuation area)"	3	0	3	100
"543"	"Emphysema distribution in smoking"	5	3	2	62.5
"544"	"Emphysema imaging phenotypes"	12	5	7	70.5882352941176
"545"	"End-stage coagulation"	15	5	10	75
"546"	"End-stage renal disease in Type 1 diabetics"	1	1	0	50
"547"	"Endometrial cancer"	4	1	3	80
"548"	"Endometrial cancer (endometrioid histology)"	1	1	0	50
"549"	"Endometrial cancer (Non-endometrioid histology)"	1	1	0	50
"550"	"Endometrial endometrioid carcinoma"	1	0	1	100
"551"	"Endometriosis"	20	14	6	58.8235294117647
"552"	"Endometriosis or depression (pleiotropy)"	1	0	1	100
"553"	"Endometriosis or migraine"	2	0	2	100
"554"	"Endothelial growth factor levels"	1	1	0	50
"555"	"Energy expenditure (24h)"	1	1	0	50
"556"	"Energy intake"	1	1	0	50
"557"	"Eosinophil counts"	82	57	25	58.9928057553957
"558"	"Eosinophil percentage of granulocytes"	13	6	7	68.4210526315789
"559"	"Eosinophil percentage of white cells"	37	23	14	61.6666666666667
"560"	"Eosinophilic esophagitis"	1	0	1	100
"561"	"Eosinophilic esophagitis (pediatric)"	1	0	1	100
"562"	"Eotaxin levels"	3	3	0	50
"563"	"Epilepsy"	3	0	3	100
"564"	"Epilepsy (remission after treatment)"	1	1	0	50
"565"	"Epithelial ovarian cancer"	10	8	2	55.5555555555556
"566"	"Epstein Barr virus nuclear antigen 1 IgG levels"	8	6	2	57.1428571428571
"567"	"Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis"	1	1	0	50
"568"	"Erectile dysfunction in type 1 diabetes"	1	1	0	50
"569"	"Erythema nodosum in inflammatory bowel disease"	2	2	0	50
"570"	"Erythrocyte cadmium concentration"	1	1	0	50
"571"	"Erythrocyte cadmium concentration in never smokers"	2	2	0	50
"572"	"Erythrocyte sedimentation rate"	1	0	1	100
"573"	"Esophageal adenocarcinoma"	1	1	0	50
"574"	"Esophageal adenocarcinoma x pack-years of smoking exposure interaction"	1	0	1	100
"575"	"Esophageal cancer"	3	1	2	75
"576"	"Esophageal cancer (squamous cell)"	3	0	3	100
"577"	"Esophageal cancer and gastric cancer"	1	0	1	100
"578"	"Esophageal squamous cell carcinoma"	5	2	3	71.4285714285714
"579"	"Essential tremor"	2	1	1	66.6666666666667
"580"	"Estimated glomerular filtration rate"	94	53	41	63.9455782312925
"581"	"Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect)"	1	1	0	50
"582"	"Estimated glomerular filtration rate in diabetes"	4	0	4	100
"583"	"Estimated glomerular filtration rate in non-diabetics"	12	6	6	66.6666666666667
"584"	"Estradiol levels"	5	3	2	62.5
"585"	"Estrone levels"	1	0	1	100
"586"	"Eudaimonic well-being"	2	2	0	50
"587"	"Evening vs. morning chronotype (sMEQ score)"	1	1	0	50
"588"	"Ewing sarcoma"	3	3	0	50
"589"	"Exfoliation glaucoma or exfoliation syndrome"	1	0	1	100
"590"	"Exfoliation syndrome"	2	2	0	50
"591"	"Exhaled nitric oxide output"	1	1	0	50
"592"	"Experiencing mood swings"	4	1	3	80
"593"	"Extranodal natural killer T-cell lymphoma (nasal type)"	2	2	0	50
"594"	"Extremely high intelligence"	1	1	0	50
"595"	"Eye color"	7	3	4	70
"596"	"Eye color traits"	2	1	1	66.6666666666667
"597"	"F-cell distribution in sickle cell anaemia"	4	2	2	66.6666666666667
"598"	"Facial morphology"	3	1	2	75
"599"	"Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)"	1	1	0	50
"600"	"Facial morphology (factor 16)"	2	2	0	50
"601"	"Facial morphology (factor 7, width of cartilaginous portion of nose)"	1	1	0	50
"602"	"Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)"	1	1	0	50
"603"	"Facial pigmentation"	1	1	0	50
"604"	"Facial pigmentation measurement (polar light)"	1	1	0	50
"605"	"Facial pigmentation measurement (UV light)"	1	1	0	50
"606"	"Facial wrinkles"	2	2	0	50
"607"	"Factor VII activity"	5	3	2	62.5
"608"	"Factor VII activity or levels"	1	1	0	50
"609"	"Factor VIII levels"	3	3	0	50
"610"	"Fagerstr**m test for nicotine dependence"	1	0	1	100
"611"	"Familial lung cancer"	2	1	1	66.6666666666667
"612"	"Family history of Alzheimer's disease"	6	4	2	60
"613"	"Fasting blood glucose"	30	15	15	66.6666666666667
"614"	"Fasting blood glucose (BMI interaction)"	14	8	6	63.6363636363636
"615"	"Fasting blood glucose adjusted for BMI"	3	3	0	50
"616"	"Fasting blood insulin"	9	5	4	64.2857142857143
"617"	"Fasting blood insulin (BMI interaction)"	11	3	8	78.5714285714286
"618"	"Fasting blood insulin adjusted for BMI"	1	1	0	50
"619"	"Fasting blood proinsulin levels"	2	0	2	100
"620"	"Fasting glucose change (long-term)"	3	2	1	60
"621"	"Fasting insulin (dietary factor interaction)"	4	4	0	50
"622"	"Fasting plasma glucose"	5	0	5	100
"623"	"Fasting plasma glucose (childhood)"	1	1	0	50
"624"	"Fasting triglyceride levels"	2	0	2	100
"625"	"Fat body mass"	1	1	0	50
"626"	"Fatty acid desaturase activity (adipose tissue)"	1	1	0	50
"627"	"Fatty acid desaturase activity (serum)"	3	3	0	50
"628"	"Febrile seizures"	6	3	3	66.6666666666667
"629"	"Febrile seizures (MMR vaccine-related)"	8	4	4	66.6666666666667
"630"	"Febrile seizures (MMR vaccine-unrelated)"	3	2	1	60
"631"	"Feeling fed-up"	3	3	0	50
"632"	"Feeling guilty"	1	1	0	50
"633"	"Feeling hurt"	4	3	1	57.1428571428571
"634"	"Feeling miserable"	6	1	5	85.7142857142857
"635"	"Feeling nervous"	7	3	4	70
"636"	"Feeling tense"	3	1	2	75
"637"	"Feeling worry"	2	0	2	100
"638"	"Femoral neck bone mineral density"	25	15	10	62.5
"639"	"Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass"	1	0	1	100
"640"	"Femoral neck size"	1	1	0	50
"641"	"Fetal hemoglobin levels"	1	1	0	50
"642"	"FEV1"	15	10	5	60
"643"	"Fibrinogen"	12	7	5	63.1578947368421
"644"	"Fibrinogen levels"	2	1	1	66.6666666666667
"645"	"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)"	3	2	1	60
"646"	"Fibroblast growth factor 23 levels"	1	1	0	50
"647"	"Fibroblast growth factor basic levels"	1	0	1	100
"648"	"Folate pathway vitamin levels"	3	3	0	50
"649"	"Follicular lymphoma"	7	5	2	58.3333333333333
"650"	"Follistatin levels"	2	0	2	100
"651"	"Food allergy"	2	1	1	66.6666666666667
"652"	"Food antigen IgG levels"	1	1	0	50
"653"	"Forced expiratory volume in 1 second (environmental tobacco smoke interaction)"	1	0	1	100
"654"	"Forced expiratory volume in 1 second (occupational environmental exposures interaction)"	3	2	1	60
"655"	"Forehead morphology"	1	0	1	100
"656"	"Fractional excretion of metabolites in chronic kidney disease"	1	1	0	50
"657"	"Fractional exhaled nitric oxide (childhood)"	4	4	0	50
"658"	"Fractures"	12	7	5	63.1578947368421
"659"	"Freckles"	1	1	0	50
"660"	"Freckling"	2	2	0	50
"661"	"Free thyroxine concentration"	2	1	1	66.6666666666667
"662"	"Frontotemporal dementia"	2	1	1	66.6666666666667
"663"	"Full scale intelligence quotient (cesarean section interaction)"	1	1	0	50
"664"	"Fulminant type 1 diabetes"	3	2	1	60
"665"	"Gait speed in old age"	3	1	2	75
"666"	"Galanin peptide levels"	1	0	1	100
"667"	"Gallbladder cancer"	1	1	0	50
"668"	"Gallstone disease"	3	1	2	75
"669"	"Gambling"	2	2	0	50
"670"	"Gastric adenocarcinoma (histologically verified)"	1	0	1	100
"671"	"Gastric cancer"	4	2	2	66.6666666666667
"672"	"Gastrointestinal infection"	2	1	1	66.6666666666667
"673"	"General cognitive ability"	32	18	14	64
"674"	"General factor of neuroticism"	17	9	8	65.3846153846154
"675"	"General risk tolerance (MTAG)"	19	11	8	63.3333333333333
"676"	"Generalized epilepsy"	4	2	2	66.6666666666667
"677"	"Gestational age at birth (child effect)"	1	1	0	50
"678"	"Gestational age at birth (maternal effect)"	1	0	1	100
"679"	"Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)"	1	1	0	50
"680"	"Gestational insulin sensitivity"	1	0	1	100
"681"	"Giant cell arteritis"	1	1	0	50
"682"	"GIP levels in response to oral glucose tolerance test (120 minutes)"	3	3	0	50
"683"	"GIP levels in response to oral glucose tolerance test (fasting)"	1	1	0	50
"684"	"Glaucoma"	12	10	2	54.5454545454545
"685"	"Glaucoma (exfoliation)"	1	0	1	100
"686"	"Glaucoma (high intraocular pressure)"	2	1	1	66.6666666666667
"687"	"Glaucoma (low intraocular pressure)"	1	1	0	50
"688"	"Glaucoma (multi-trait analysis)"	3	3	0	50
"689"	"Glaucoma (primary angle closure)"	8	6	2	57.1428571428571
"690"	"Glaucoma (primary open-angle)"	15	12	3	55.5555555555556
"691"	"Glioblastoma"	2	2	0	50
"692"	"Glioblastoma (age-stratified)"	2	2	0	50
"693"	"Glioma"	14	10	4	58.3333333333333
"694"	"Glioma (high-grade)"	4	1	3	80
"695"	"Glomerular filtration rate"	6	3	3	66.6666666666667
"696"	"Glomerular filtration rate (creatinine)"	20	14	6	58.8235294117647
"697"	"Glomerular filtration rate change in heart transplantation"	1	0	1	100
"698"	"Glomerular filtration rate in chronic kidney disease"	4	2	2	66.6666666666667
"699"	"Glomerular filtration rate in diabetes"	2	0	2	100
"700"	"Glomerular filtration rate in non diabetics (creatinine)"	14	8	6	63.6363636363636
"701"	"Glucagon levels in response to oral glucose tolerance test (120 minutes)"	3	1	2	75
"702"	"Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-120 minutes)"	1	1	0	50
"703"	"Glucocorticoid-induced osteonecrosis"	2	0	2	100
"704"	"Glucosuria"	1	0	1	100
"705"	"Glucosuria (mild)"	1	0	1	100
"706"	"Glucosuria (moderate to severe)"	1	0	1	100
"707"	"Glycated hemoglobin levels"	33	16	17	67.3469387755102
"708"	"Glycemic traits"	2	0	2	100
"709"	"Glycemic traits (pregnancy)"	2	0	2	100
"710"	"Glycerophospholipid levels"	33	33	0	50
"711"	"Glycine levels"	11	4	7	73.3333333333333
"712"	"Gondoic acid (20:1n-9) levels"	2	2	0	50
"713"	"Gout"	10	5	5	66.6666666666667
"714"	"Gout (combined type)"	1	0	1	100
"715"	"Gout vs. Hyperuricemia"	2	1	1	66.6666666666667
"716"	"Granulocyte count"	15	11	4	57.6923076923077
"717"	"Granulocyte percentage of myeloid white cells"	12	8	4	60
"718"	"Graves' disease"	11	8	3	57.8947368421053
"719"	"group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP"	1	0	1	100
"720"	"Growth-regulated protein alpha levels"	3	1	2	75
"721"	"Gut microbiota (bacterial taxa)"	10	4	6	71.4285714285714
"722"	"Gut microbiota (bacterial taxa, rank normal transformation method)"	3	2	1	60
"723"	"Gut microbiota (functional units)"	15	11	4	57.6923076923077
"724"	"Gut microbiota alpha diversity (Chao1 index)"	3	3	0	50
"725"	"Gut microbiota alpha diversity (PD_whole_tree index)"	2	2	0	50
"726"	"Gut microbiota beta diversity (weighted UniFrac distance)"	1	1	0	50
"727"	"Gut microbiota relative abundance (Eubacterium belonging to family Erysipelotrichaceae)"	1	1	0	50
"728"	"Gut microbiota relative abundance (Faecalibacterium)"	2	1	1	66.6666666666667
"729"	"Gut microbiota relative abundance (Oscillospira)"	1	1	0	50
"730"	"Gut microbiota relative abundance (Ruminococcus belonging to family Lachnospiraceae)"	2	2	0	50
"731"	"Gut microbiota relative abundance (Streptococcus)"	1	1	0	50
"732"	"Gut microbiota relative abundance (Sutterella)"	1	1	0	50
"733"	"Gut microbiota relative abundance (unclassified genus belonging to family Erysipelotrichaceae)"	3	3	0	50
"734"	"Gut microbiota relative abundance (unclassified genus belonging to family Ruminococcaceae)"	3	2	1	60
"735"	"Gut microbiota relative abundance (unclassified genus belonging to the order Clostridiales)"	1	0	1	100
"736"	"Hair color"	13	9	4	59.0909090909091
"737"	"Hair morphology"	2	1	1	66.6666666666667
"738"	"Hand grip strength"	11	8	3	57.8947368421053
"739"	"Hashimoto thyroiditis versus Graves' disease"	1	1	0	50
"740"	"Hay fever and/or eczema"	19	10	9	65.5172413793103
"741"	"HbA2 levels"	1	1	0	50
"742"	"HDL cholesterol"	125	86	39	59.2417061611374
"743"	"HDL Cholesterol - Triglycerides (HDLC-TG)"	3	1	2	75
"744"	"HDL cholesterol levels"	161	83	78	65.983606557377
"745"	"HDL cholesterol levels in current drinkers"	27	16	11	62.7906976744186
"746"	"HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)"	30	19	11	61.2244897959184
"747"	"HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)"	30	19	11	61.2244897959184
"748"	"HDL cholesterol x physical activity interaction (2df test)"	4	4	0	50
"749"	"Head circumference (infant)"	1	1	0	50
"750"	"Headache"	3	3	0	50
"751"	"Healthspan"	1	0	1	100
"752"	"Hearing loss in Charcot-Marie-Tooth disease 1A"	1	1	0	50
"753"	"Heart failure"	2	1	1	66.6666666666667
"754"	"Heart rate"	20	8	12	71.4285714285714
"755"	"Heart rate increase in response to exercise"	1	1	0	50
"756"	"Heart rate response to beta blockers (atenolol add-on therapy)"	1	1	0	50
"757"	"Heart rate response to beta blockers (atenolol monotherapy)"	5	0	5	100
"758"	"Heart rate response to exercise"	4	3	1	57.1428571428571
"759"	"Heart rate response to recovery post exercise"	7	4	3	63.6363636363636
"760"	"Heart rate response to recovery post exercise (10 sec)"	2	1	1	66.6666666666667
"761"	"Heart rate response to recovery post exercise (20 sec)"	1	1	0	50
"762"	"Heart rate response to recovery post exercise (30 sec)"	1	0	1	100
"763"	"Heart rate response to recovery post exercise (40 sec)"	1	0	1	100
"764"	"Heart rate response to recovery post exercise (50 sec)"	3	2	1	60
"765"	"Heart rate variability traits (pvRSA/HF)"	3	0	3	100
"766"	"Heart rate variability traits (RMSSD)"	3	0	3	100
"767"	"Heart rate variability traits (SDNN)"	2	0	2	100
"768"	"Heavy menstrual bleeding"	1	0	1	100
"769"	"Hedonic well-being"	1	1	0	50
"770"	"Heel bone mineral density"	161	73	88	68.8034188034188
"771"	"Heel bone mineral density (MTAG)"	1	1	0	50
"772"	"Height"	464	277	187	62.6180836707152
"773"	"Height adjusted BMI"	2	1	1	66.6666666666667
"774"	"Help-seeking from a psychiatrist"	1	0	1	100
"775"	"Hematocrit"	107	76	31	58.4699453551913
"776"	"Hematological and biochemical traits"	14	8	6	63.6363636363636
"777"	"Hematological parameters"	7	4	3	63.6363636363636
"778"	"Hematology traits"	3	2	1	60
"779"	"Hematoma volume in lobar spontaneous intracerebral hemorrhage"	1	0	1	100
"780"	"Hemoglobin"	36	27	9	57.1428571428571
"781"	"Hemoglobin A1c levels"	1	1	0	50
"782"	"Hemoglobin concentration"	70	41	29	63.0630630630631
"783"	"Hemoglobin levels"	34	28	6	54.8387096774194
"784"	"Hemostatic factors and hematological phenotypes"	2	2	0	50
"785"	"Hepatitis B"	5	2	3	71.4285714285714
"786"	"Hepatitis B (viral clearance)"	2	0	2	100
"787"	"Hepatitis B surface antigen seroclearance in chronic hepatitis B infection"	1	1	0	50
"788"	"Hepatitis B virus-related hepatocellular carcinoma"	1	1	0	50
"789"	"Hepatitis C (spontaneous viral clearance)"	3	3	0	50
"790"	"Hepatitis C induced liver cirrhosis"	1	1	0	50
"791"	"Hepatitis C induced liver fibrosis"	1	1	0	50
"792"	"Hepatocellular carcinoma"	3	3	0	50
"793"	"Hepatocellular carcinoma in hepatitis B infection"	2	0	2	100
"794"	"Hepatocyte growth factor levels"	1	0	1	100
"795"	"Hepcidin levels"	1	1	0	50
"796"	"Hepcidin/ferritin ratio"	4	3	1	57.1428571428571
"797"	"Hepcidin/transferrin saturation ratio"	2	2	0	50
"798"	"High-grade serous ovarian cancer"	3	2	1	60
"799"	"High density lipoprotein cholesterol levels"	341	155	186	68.75
"800"	"High light scatter reticulocyte count"	40	21	19	65.5737704918033
"801"	"High light scatter reticulocyte percentage of red cells"	37	21	16	63.7931034482759
"802"	"High myopia"	1	0	1	100
"803"	"Highest math class taken"	11	7	4	61.1111111111111
"804"	"Highest math class taken (MTAG)"	54	30	24	64.2857142857143
"805"	"Hip bone mineral content accrual during adolescent growth spurt"	1	1	0	50
"806"	"Hip bone size"	5	2	3	71.4285714285714
"807"	"Hip circumference"	50	26	24	65.7894736842105
"808"	"Hip circumference (psychosocial stress interaction)"	1	0	1	100
"809"	"Hip circumference adjusted for BMI"	89	50	39	64.0287769784173
"810"	"Hip minimal joint space width"	1	1	0	50
"811"	"Hippocampal atrophy"	2	1	1	66.6666666666667
"812"	"Hippocampal atrophy rate"	1	1	0	50
"813"	"Hippocampal sclerosis of aging"	1	1	0	50
"814"	"Hippocampal subfield CA4 volume"	1	1	0	50
"815"	"Hippocampal volume"	5	0	5	100
"816"	"Hirschsprung disease"	2	0	2	100
"817"	"HIV-1 control"	6	4	2	60
"818"	"HIV-1 susceptibility"	1	1	0	50
"819"	"HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)"	1	0	1	100
"820"	"Hodgkin's lymphoma"	3	3	0	50
"821"	"Homeostasis model assessment of beta-cell function"	7	4	3	63.6363636363636
"822"	"Homeostasis model assessment of beta-cell function (dietary factor interaction)"	2	2	0	50
"823"	"Homeostasis model assessment of insulin resistance"	1	0	1	100
"824"	"Homeostasis model assessment of insulin resistance (dietary factor interaction)"	4	4	0	50
"825"	"Homoarginine levels"	1	1	0	50
"826"	"Homocysteine levels"	9	8	1	52.9411764705882
"827"	"Hormone measurements"	1	1	0	50
"828"	"Hospital contact for infections"	3	0	3	100
"829"	"Household income"	5	5	0	50
"830"	"Household income (MTAG)"	21	14	7	60
"831"	"Hyperemesis gravidarum"	1	0	1	100
"832"	"Hypersomnia (HLA-DQB1*06:02 negative)"	2	2	0	50
"833"	"Hypertension"	52	27	25	65.8227848101266
"834"	"Hyperthyroidism"	1	0	1	100
"835"	"Hypertriglyceridemia"	2	0	2	100
"836"	"Hypospadias"	13	7	6	65
"837"	"Hypothyroidism"	8	8	0	50
"838"	"Ideal cardiovascular health (clinical)"	1	1	0	50
"839"	"Idiopathic dilated cardiomyopathy"	1	1	0	50
"840"	"Idiopathic membranous nephropathy"	1	1	0	50
"841"	"Idiopathic pulmonary fibrosis"	4	1	3	80
"842"	"IgA levels"	3	3	0	50
"843"	"IgA nephropathy"	32	27	5	54.2372881355932
"844"	"IgE grass sensitization"	4	3	1	57.1428571428571
"845"	"IgE levels"	5	4	1	55.5555555555556
"846"	"IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis)"	2	1	1	66.6666666666667
"847"	"IgG digalactosylation phenotypes (multivariate analysis)"	2	1	1	66.6666666666667
"848"	"IgG disialylation phenotypes (multivariate analysis)"	2	1	1	66.6666666666667
"849"	"IgG fucosylation phenotypes (multivariate analysis)"	1	0	1	100
"850"	"IgG galactosylation phenotypes (multivariate analysis)"	3	1	2	75
"851"	"IgG glycosylation"	202	71	131	73.992673992674
"852"	"IgG monogalactosylation phenotypes (multivariate analysis)"	2	1	1	66.6666666666667
"853"	"IgG N-glycosylation phenotypes (multivariate analysis)"	6	2	4	75
"854"	"IgG sialylation phenotypes (multivariate analysis)"	2	1	1	66.6666666666667
"855"	"IgM levels"	6	2	4	75
"856"	"Immature fraction of reticulocytes"	32	20	12	61.5384615384615
"857"	"Immune reponse to smallpox (secreted IFN-alpha)"	2	2	0	50
"858"	"Immune reponse to smallpox (secreted TNF-alpha)"	1	1	0	50
"859"	"Immune response to measles vaccine (measles-specific neutralising antibody titre)"	1	0	1	100
"860"	"Incident atrial fibrillation"	1	0	1	100
"861"	"Infant head circumference (MTAG)"	3	2	1	60
"862"	"Infant length"	10	8	2	55.5555555555556
"863"	"Infantile hypertrophic pyloric stenosis"	9	5	4	64.2857142857143
"864"	"Inflammatory biomarkers"	3	1	2	75
"865"	"Inflammatory bowel disease"	98	58	40	62.8205128205128
"866"	"Information processing speed"	9	5	4	64.2857142857143
"867"	"Inhibitory control"	1	1	0	50
"868"	"Initial pursuit acceleration"	1	0	1	100
"869"	"Insomnia"	24	14	10	63.1578947368421
"870"	"Insomnia symptoms (never/rarely vs. sometimes/usually)"	1	0	1	100
"871"	"Insomnia symptoms (never/rarely vs. usually)"	4	1	3	80
"872"	"Insulin-like growth factors"	2	2	0	50
"873"	"Insulin-related traits"	2	2	0	50
"874"	"Insulin disposition index"	1	1	0	50
"875"	"Insulin levels in response to oral glucose tolerance test (30 minutes)"	2	1	1	66.6666666666667
"876"	"Insulin resistance/response"	2	0	2	100
"877"	"Insulinogenic index"	1	1	0	50
"878"	"Intake of total sugars"	3	3	0	50
"879"	"Intelligence"	31	20	11	60.7843137254902
"880"	"Intelligence (childhood)"	6	5	1	54.5454545454545
"881"	"Intelligence (MTAG)"	33	21	12	61.1111111111111
"882"	"Interferon gamma-induced protein 10 levels"	2	0	2	100
"883"	"Interferon gamma levels"	1	1	0	50
"884"	"Interleukin-1-beta levels"	2	1	1	66.6666666666667
"885"	"Interleukin-1-receptor antagonist levels"	3	1	2	75
"886"	"Interleukin-10 levels"	3	2	1	60
"887"	"Interleukin-12p70 levels"	3	3	0	50
"888"	"Interleukin-13 levels"	3	1	2	75
"889"	"Interleukin-16 levels"	3	0	3	100
"890"	"Interleukin-17 levels"	1	0	1	100
"891"	"Interleukin-18 levels"	4	1	3	80
"892"	"interleukin-18 receptor 1 levels"	1	1	0	50
"893"	"Interleukin-2 levels"	1	1	0	50
"894"	"Interleukin-2 receptor antagonist levels"	3	2	1	60
"895"	"Interleukin-4 levels"	1	0	1	100
"896"	"Interleukin-5 levels"	1	0	1	100
"897"	"Interleukin-8 levels"	1	1	0	50
"898"	"Interleukin-9 levels"	3	0	3	100
"899"	"interleukin 17 receptor B levels"	1	1	0	50
"900"	"Interstitial lung disease"	5	3	2	62.5
"901"	"Intertrochanteric region size"	2	2	0	50
"902"	"Intracerebral hemorrhage"	1	0	1	100
"903"	"Intracranial aneurysm"	18	7	11	72
"904"	"Intracranial volume"	1	1	0	50
"905"	"Intraocular pressure"	84	47	37	64.1221374045801
"906"	"Intraocular pressure and central corneal thickness (multi-trait analysis)"	1	1	0	50
"907"	"Invasive epithelial ovarian cancer"	3	3	0	50
"908"	"Iris characteristics"	7	5	2	58.3333333333333
"909"	"Iris color (b* coordinate)"	2	0	2	100
"910"	"Iris color (L* coordinate)"	1	1	0	50
"911"	"Iron levels"	1	0	1	100
"912"	"Iron status biomarkers"	13	9	4	59.0909090909091
"913"	"Iron status biomarkers (ferritin levels)"	5	3	2	62.5
"914"	"Iron status biomarkers (iron levels)"	5	3	2	62.5
"915"	"Iron status biomarkers (total iron binding capacity)"	6	2	4	75
"916"	"Iron status biomarkers (transferrin levels)"	7	5	2	58.3333333333333
"917"	"Iron status biomarkers (transferrin saturation)"	7	4	3	63.6363636363636
"918"	"Irritable bowel syndrome"	3	2	1	60
"919"	"Irritable mood"	7	5	2	58.3333333333333
"920"	"Ischemic stroke"	6	1	5	85.7142857142857
"921"	"Ischemic stroke (cardioembolic)"	1	0	1	100
"922"	"Isovolumetric relaxation time"	1	0	1	100
"923"	"Itch intensity from mosquito bite"	6	4	2	60
"924"	"Itch intensity from mosquito bite adjusted by bite size"	16	6	10	72.7272727272727
"925"	"Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)"	1	1	0	50
"926"	"Kawasaki disease"	10	5	5	66.6666666666667
"927"	"Keloid"	1	1	0	50
"928"	"Keratinocyte cancer (MTAG)"	16	8	8	66.6666666666667
"929"	"Kidney injury molecule 1 levels"	2	2	0	50
"930"	"Kidney stones"	4	2	2	66.6666666666667
"931"	"Knee osteoarthritis"	2	2	0	50
"932"	"Knee pain"	1	1	0	50
"933"	"Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis"	1	0	1	100
"934"	"Large artery stroke"	2	1	1	66.6666666666667
"935"	"Late-onset Alzheimer's disease"	2	1	1	66.6666666666667
"936"	"Latent naming speed"	1	1	0	50
"937"	"LDL (oxidized)"	1	0	1	100
"938"	"LDL cholesterol"	92	60	32	60.5263157894737
"939"	"LDL cholesterol levels"	137	83	54	62.2727272727273
"940"	"LDL cholesterol levels in current drinkers"	24	17	7	58.5365853658537
"941"	"LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)"	30	20	10	60
"942"	"LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)"	31	19	12	62
"943"	"LDL cholesterol x physical activity interaction (2df test)"	8	4	4	66.6666666666667
"944"	"LDL peak particle diameter (total fat intake interaction)"	1	0	1	100
"945"	"Lead levels in blood"	2	2	0	50
"946"	"Lectin-like oxidized LDL receptor 1 levels"	2	1	1	66.6666666666667
"947"	"Left-handedness"	2	2	0	50
"948"	"Left ventricle diastolic internal dimension"	1	1	0	50
"949"	"Left ventricle wall thickness"	2	0	2	100
"950"	"Leisure-time exercise behaviour"	1	0	1	100
"951"	"Length of menstrual cycle"	1	0	1	100
"952"	"Lentiform nucleus volume"	5	3	2	62.5
"953"	"Leprosy"	11	4	7	73.3333333333333
"954"	"Leukocyte telomere length"	8	7	1	53.3333333333333
"955"	"Levodopa-induced dyskinesia in levodopa treated Parkinson's disease"	1	1	0	50
"956"	"Levodopa wearing off effect (time symptoms uncontrolled) in Parkinson's disease (response to zonisamide)"	2	0	2	100
"957"	"Lewy body disease"	1	1	0	50
"958"	"Life satisfaction"	5	4	1	55.5555555555556
"959"	"Life threatening arrhythmia"	1	1	0	50
"960"	"Lifetime average cigarettes per day in chronic obstructive pulmonary disease"	2	0	2	100
"961"	"Lifetime smoking index"	7	4	3	63.6363636363636
"962"	"Limited cutaneous systemic scleroderma"	1	1	0	50
"963"	"Lipid traits"	10	8	2	55.5555555555556
"964"	"Lipoprotein-associated phospholipase A2 activity and mass"	10	5	5	66.6666666666667
"965"	"Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease"	1	1	0	50
"966"	"Lipoprotein-associated phospholipase A2 activity change in response to statin therapy"	1	1	0	50
"967"	"Lipoprotein (a) levels"	4	3	1	57.1428571428571
"968"	"Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention)"	1	0	1	100
"969"	"Lipoprotein phospholipase A2 activity in cardiovascular disease"	3	3	0	50
"970"	"Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms"	1	1	0	50
"971"	"Liver enzyme levels"	2	2	0	50
"972"	"Liver enzyme levels (alanine transaminase)"	2	0	2	100
"973"	"Liver enzyme levels (alkaline phosphatase)"	4	3	1	57.1428571428571
"974"	"Liver enzyme levels (gamma-glutamyl transferase)"	14	5	9	73.6842105263158
"975"	"Liver fat content (MRI proton density fat fraction measure)"	2	1	1	66.6666666666667
"976"	"Liver fibrosis and steatohepatitis severity (MRI cT1 measure)"	1	1	0	50
"977"	"Liver injury in anti-tuberculosis drug treatment"	1	0	1	100
"978"	"Lobe size"	1	1	0	50
"979"	"Local histogram emphysema pattern"	15	3	12	83.3333333333333
"980"	"Logical memory (delayed recall)"	1	1	0	50
"981"	"Logical memory (immediate recall)"	1	1	0	50
"982"	"Logical memory (immediate recall) in normal cognition"	1	1	0	50
"983"	"Loneliness"	1	1	0	50
"984"	"Loneliness (MTAG)"	1	1	0	50
"985"	"Longevity"	4	2	2	66.6666666666667
"986"	"Longevity (90 years and older)"	3	1	2	75
"987"	"Longevity (age >90th survival percentile)"	5	2	3	71.4285714285714
"988"	"Longevity (age >99th survival percentile)"	5	2	3	71.4285714285714
"989"	"Longitudinal alcohol consumption"	3	0	3	100
"990"	"Low-grade serous and serous borderline ovarian cancer"	4	3	1	57.1428571428571
"991"	"Low density lipoprotein cholesterol levels"	277	118	159	70.126582278481
"992"	"Low density lipoprotein cholesterol levels (on statin treatment)"	2	2	0	50
"993"	"Low hand grip strength (60 years and older) (EWGSOP)"	2	2	0	50
"994"	"Low high density lipoprotein cholesterol levels"	2	1	1	66.6666666666667
"995"	"Low tan response"	2	2	0	50
"996"	"Low urine pH"	1	1	0	50
"997"	"Lp (a) levels"	3	3	0	50
"998"	"Lumbar spine bone mineral density"	28	17	11	62.2222222222222
"999"	"Lumbar spine bone mineral density (integral)"	4	3	1	57.1428571428571
"1000"	"Lumbar spine bone mineral density (trabecular)"	1	1	0	50
"1001"	"Lung adenocarcinoma"	14	5	9	73.6842105263158
"1002"	"Lung cancer"	14	5	9	73.6842105263158
"1003"	"Lung cancer in ever smokers"	5	2	3	71.4285714285714
"1004"	"Lung cancer in never smokers"	1	1	0	50
"1005"	"Lung disease severity in cystic fibrosis"	3	3	0	50
"1006"	"Lung function"	1	1	0	50
"1007"	"Lung function (FEV1)"	1	1	0	50
"1008"	"Lung function (FEV1/FVC)"	21	11	10	65.625
"1009"	"Lung function (forced vital capacity)"	3	3	0	50
"1010"	"Lung function (FVC)"	14	9	5	60.8695652173913
"1011"	"Lung function (low FEV1 vs high FEV1)"	1	1	0	50
"1012"	"Lung function in never smokers (low FEV1 vs high FEV1)"	1	1	0	50
"1013"	"Lupus nephritis in systemic lupus erythematosus"	2	1	1	66.6666666666667
"1014"	"Lymphocyte counts"	114	75	39	60.3174603174603
"1015"	"Lymphocyte percentage of white cells"	29	21	8	58
"1016"	"Lymphocytic leukemia"	1	0	1	100
"1017"	"Lymphoma"	1	1	0	50
"1018"	"Macrophage colony stimulating factor levels"	1	0	1	100
"1019"	"Macrophage inflammatory protein 1a levels"	1	0	1	100
"1020"	"Macrophage inflammatory protein 1b levels"	9	0	9	100
"1021"	"Macrophage Migration Inhibitory Factor levels"	2	1	1	66.6666666666667
"1022"	"Magnesium levels"	6	4	2	60
"1023"	"Major depressive disorder"	24	15	9	61.5384615384615
"1024"	"Major depressive disorder (broad)"	2	1	1	66.6666666666667
"1025"	"Major depressive disorder (probable)"	1	0	1	100
"1026"	"Major depressive disorder in trauma exposed individuals"	6	2	4	75
"1027"	"Malaria"	3	0	3	100
"1028"	"Malate levels"	1	0	1	100
"1029"	"Male-pattern baldness"	55	33	22	62.5
"1030"	"Male puberty timing (age at voice breaking MTAG)"	5	3	2	62.5
"1031"	"Male puberty timing (early vs. average onset facial hair)"	3	2	1	60
"1032"	"Male puberty timing (early vs. average onset voice breaking)"	1	1	0	50
"1033"	"Male puberty timing (late vs. average onset facial hair)"	3	2	1	60
"1034"	"Male puberty timing (late vs. average onset voice breaking)"	2	1	1	66.6666666666667
"1035"	"Mammographic density (dense area)"	4	0	4	100
"1036"	"Mammographic density (non-dense area)"	1	1	0	50
"1037"	"Matrix metalloproteinase-10 levels"	3	2	1	60
"1038"	"Matrix metalloproteinase-12 levels"	1	0	1	100
"1039"	"Matrix metalloproteinase-3 levels"	2	1	1	66.6666666666667
"1040"	"Matrix metalloproteinase levels"	2	2	0	50
"1041"	"Maximum retinal arteriolar tortuosity"	1	1	0	50
"1042"	"Mean arterial pressure"	40	27	13	59.7014925373134
"1043"	"Mean arterial pressure (long-term average)"	1	0	1	100
"1044"	"Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)"	4	1	3	80
"1045"	"Mean arterial pressure x alcohol consumption interaction (2df test)"	5	4	1	55.5555555555556
"1046"	"Mean corpuscular hemoglobin"	116	67	49	63.3879781420765
"1047"	"Mean corpuscular hemoglobin concentration"	49	23	26	68.0555555555556
"1048"	"Mean corpuscular volume"	136	81	55	62.6728110599078
"1049"	"Mean platelet volume"	166	69	97	70.6382978723404
"1050"	"Mean reticulocyte volume"	26	19	7	57.7777777777778
"1051"	"Mean spheric corpuscular volume"	46	34	12	57.5
"1052"	"Medication use (adrenergics, inhalants)"	3	3	0	50
"1053"	"Medication use (agents acting on the renin-angiotensin system)"	10	8	2	55.5555555555556
"1054"	"Medication use (anilides)"	1	1	0	50
"1055"	"Medication use (anti-inflammatory and antirheumatic products, non-steroids)"	1	1	0	50
"1056"	"Medication use (antiglaucoma preparations and miotics)"	3	2	1	60
"1057"	"Medication use (antimigraine preparations)"	3	3	0	50
"1058"	"Medication use (antithrombotic agents)"	2	2	0	50
"1059"	"Medication use (beta blocking agents)"	1	1	0	50
"1060"	"Medication use (calcium channel blockers)"	8	8	0	50
"1061"	"Medication use (diuretics)"	3	3	0	50
"1062"	"Medication use (drugs affecting bone structure and mineralization)"	1	0	1	100
"1063"	"Medication use (drugs used in diabetes)"	6	4	2	60
"1064"	"Medication use (HMG CoA reductase inhibitors)"	13	11	2	54.1666666666667
"1065"	"Medication use (immunosuppressants)"	1	1	0	50
"1066"	"Medication use (salicylic acid and derivatives)"	3	3	0	50
"1067"	"Medication use (thyroid preparations)"	13	11	2	54.1666666666667
"1068"	"Melanoma"	13	9	4	59.0909090909091
"1069"	"Menarche (age at onset)"	101	53	48	65.5844155844156
"1070"	"Menarche and menopause (age at onset)"	2	1	1	66.6666666666667
"1071"	"Meningioma"	1	1	0	50
"1072"	"Menopause (age at onset)"	25	13	12	65.7894736842105
"1073"	"Menstruation quality of life impact (acne)"	3	2	1	60
"1074"	"Menstruation quality of life impact (aggressiveness)"	1	1	0	50
"1075"	"Menstruation quality of life impact (increased appetite)"	1	1	0	50
"1076"	"Menstruation quality of life impact (loss of concentration)"	1	0	1	100
"1077"	"Mental health study participation (completed survey)"	1	1	0	50
"1078"	"Mental health study participation (provided email address)"	1	1	0	50
"1079"	"Merkel cell polyomavirus VP1 antibody levels"	1	0	1	100
"1080"	"Metabolic syndrome"	25	14	11	64.1025641025641
"1081"	"Metabolic syndrome (bivariate traits)"	7	2	5	77.7777777777778
"1082"	"Metabolic traits"	18	14	4	56.25
"1083"	"Metabolite levels"	22	8	14	73.3333333333333
"1084"	"Metabolite levels  (X-11787)"	3	1	2	75
"1085"	"Metabolite levels (5-HIAA)"	2	2	0	50
"1086"	"Metabolite levels (5-HIAA/ MHPG Ratio)"	1	1	0	50
"1087"	"Metabolite levels (Dihydroxy docosatrienoic acid)"	1	0	1	100
"1088"	"Metabolite levels (HVA/5-HIAA ratio)"	1	1	0	50
"1089"	"Metabolite levels (HVA/MHPG ratio)"	2	1	1	66.6666666666667
"1090"	"Metabolite levels (lipid measures)"	2	1	1	66.6666666666667
"1091"	"Metabolite levels (lipoprotein measures)"	6	5	1	54.5454545454545
"1092"	"Metabolite levels (MHPG)"	3	2	1	60
"1093"	"Metabolite levels (Pyroglutamine)"	1	0	1	100
"1094"	"Metabolite levels (small molecules and protein measures)"	4	0	4	100
"1095"	"Methadone dose in opioid dependence"	1	1	0	50
"1096"	"Methotrexate phramacokinetics (acute lymphoblastic leukemia)"	5	1	4	83.3333333333333
"1097"	"Microalbuminuria"	3	3	0	50
"1098"	"Microscopic brain infarct"	1	0	1	100
"1099"	"Middle childhood and early adolescence aggressive behavior"	1	1	0	50
"1100"	"middle facial morphology traits (quantitative measurement)"	2	1	1	66.6666666666667
"1101"	"Midline nonsyndromic craniosynostosis"	1	1	0	50
"1102"	"Migraine"	9	7	2	56.25
"1103"	"Migraine - clinic-based"	3	3	0	50
"1104"	"Migraine with aura"	1	1	0	50
"1105"	"Migraine without aura"	4	4	0	50
"1106"	"Mild to moderate chronic kidney disease"	1	0	1	100
"1107"	"Minimum ankle***brachial index"	1	0	1	100
"1108"	"Moderate to vigorous physical activity levels"	3	0	3	100
"1109"	"Modic changes"	2	0	2	100
"1110"	"Modified Stumvoll Insulin Sensitivity Index (BMI interaction)"	1	0	1	100
"1111"	"Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)"	3	0	3	100
"1112"	"Monoclonal gammopathy of undetermined significance"	1	0	1	100
"1113"	"Monocyte chemoattractant protein-1 levels"	9	5	4	64.2857142857143
"1114"	"Monocyte chemoattractant protein-4 levels"	1	1	0	50
"1115"	"Monocyte count"	117	75	42	60.9375
"1116"	"Monocyte percentage of white cells"	37	27	10	57.8125
"1117"	"Monokine induced by gamma interferon levels"	3	1	2	75
"1118"	"Morning person"	12	6	6	66.6666666666667
"1119"	"Morning vs. evening chronotype"	3	1	2	75
"1120"	"Morningness"	12	6	6	66.6666666666667
"1121"	"Mortality in heart failure"	2	1	1	66.6666666666667
"1122"	"Mosaic loss of chromosome Y"	1	0	1	100
"1123"	"Mosaic loss of chromosome Y (Y chromosome dosage)"	3	0	3	100
"1124"	"Mosquito bite size"	5	3	2	62.5
"1125"	"Motion sickness"	19	14	5	57.5757575757576
"1126"	"Motor fluctuations in levodopa treated Parkinson's disease"	1	1	0	50
"1127"	"Mouth ulcers"	8	5	3	61.5384615384615
"1128"	"Moyamoya disease"	2	0	2	100
"1129"	"Mucinous adenocarcinoma in colorectal cancer"	3	3	0	50
"1130"	"Mucinous ovarian carcinoma"	1	0	1	100
"1131"	"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"	3	3	0	50
"1132"	"Multiple keratinocyte cancers"	1	0	1	100
"1133"	"Multiple myeloma"	7	2	5	77.7777777777778
"1134"	"Multiple myeloma (hyperdiploidy)"	1	1	0	50
"1135"	"Multiple myeloma (IgH translocation)"	4	2	2	66.6666666666667
"1136"	"Multiple sclerosis"	92	60	32	60.5263157894737
"1137"	"Multiple system atrophy"	2	1	1	66.6666666666667
"1138"	"Multisite chronic pain"	1	1	0	50
"1139"	"Mumps"	1	0	1	100
"1140"	"Myasthenia gravis"	5	5	0	50
"1141"	"Myeloid clonal hematopoiesis"	2	1	1	66.6666666666667
"1142"	"Myeloid white cell count"	18	11	7	62.0689655172414
"1143"	"Myeloperoxidase levels"	1	1	0	50
"1144"	"Myeloproliferative neoplasms"	4	3	1	57.1428571428571
"1145"	"Myocardial infarction"	20	9	11	68.9655172413793
"1146"	"Myocardial infarction (early onset)"	6	2	4	75
"1147"	"Myocardial infarction in coronary artery disease"	1	1	0	50
"1148"	"Myopia (age of diagnosis)"	12	5	7	70.5882352941176
"1149"	"Myopia (pathological)"	5	3	2	62.5
"1150"	"Myopia (severe)"	1	0	1	100
"1151"	"N-desmethylclozapine concentration in schizophrenia"	1	1	0	50
"1152"	"N-glycan levels"	9	9	0	50
"1153"	"N-terminal prohormone brain natriuretic peptide levels"	1	0	1	100
"1154"	"Narcolepsy"	3	3	0	50
"1155"	"Narcolepsy (age of onset)"	1	1	0	50
"1156"	"Nasal polyps"	4	2	2	66.6666666666667
"1157"	"Nasopharyngeal carcinoma"	1	0	1	100
"1158"	"Neovascular age-related macular degeneration"	1	0	1	100
"1159"	"Neuranatomic and neurocognitive phenotypes"	1	0	1	100
"1160"	"Neuritic plaque"	7	4	3	63.6363636363636
"1161"	"Neuroblastoma"	9	6	3	60
"1162"	"Neuroblastoma (1p deletion)"	1	1	0	50
"1163"	"Neuroblastoma (high-risk)"	1	1	0	50
"1164"	"Neuroblastoma (MYCN amplification)"	1	1	0	50
"1165"	"Neuroblastoma or malignant cutaneous melanoma"	2	0	2	100
"1166"	"Neurociticism"	9	6	3	60
"1167"	"Neurocognitive impairment in HIV-1 infection (dichotomous)"	1	0	1	100
"1168"	"Neurofibrillary tangles"	3	1	2	75
"1169"	"Neurological blood protein biomarker levels"	7	7	0	50
"1170"	"Neuropathologic traits (pleiotropy)"	4	1	3	80
"1171"	"Neuroticism"	42	27	15	60.8695652173913
"1172"	"Neuroticism (MTAG)"	3	2	1	60
"1173"	"Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)"	1	1	0	50
"1174"	"Neutrophil count"	95	56	39	62.9139072847682
"1175"	"Neutrophil percentage of granulocytes"	10	4	6	71.4285714285714
"1176"	"Neutrophil percentage of white cells"	24	16	8	60
"1177"	"Nevus count or cutaneous melanoma"	5	1	4	83.3333333333333
"1178"	"Nicotine dependence"	4	3	1	57.1428571428571
"1179"	"Nicotine dependence symptom count"	6	5	1	54.5454545454545
"1180"	"Nicotine glucouronidation"	1	1	0	50
"1181"	"Nicotine use"	1	1	0	50
"1182"	"Nicotine withdrawal"	1	0	1	100
"1183"	"Night sleep phenotypes"	6	3	3	66.6666666666667
"1184"	"Non-albumin protein levels"	2	1	1	66.6666666666667
"1185"	"Non-alcoholic fatty liver disease activity score in non-alcoholic fatty liver disease"	3	3	0	50
"1186"	"Non-alcoholic fatty liver disease histology (lobular)"	1	1	0	50
"1187"	"Non-alcoholic fatty liver disease histology (other)"	6	3	3	66.6666666666667
"1188"	"Non-cardia gastric cancer"	3	2	1	60
"1189"	"Non-glioblastoma glioma"	4	3	1	57.1428571428571
"1190"	"Non-Hodgkin's lymphoma"	1	1	0	50
"1191"	"Non-melanoma skin cancer"	12	3	9	80
"1192"	"Non-obstructive azoospermia"	1	1	0	50
"1193"	"Non-small cell lung cancer"	5	3	2	62.5
"1194"	"Non-small cell lung cancer (survival)"	1	1	0	50
"1195"	"Non-word reading"	1	1	0	50
"1196"	"Nonalcoholic fatty liver disease"	1	1	0	50
"1197"	"Nonatopic asthma or fasting glucose levels"	1	1	0	50
"1198"	"Noncognitive aspects of educational attainment"	6	2	4	75
"1199"	"Nonsyndromic cleft lip"	1	1	0	50
"1200"	"Nonsyndromic cleft lip with cleft palate"	4	3	1	57.1428571428571
"1201"	"Nonsyndromic cleft lip with or without cleft palate"	4	3	1	57.1428571428571
"1202"	"Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test)"	2	0	2	100
"1203"	"Nonsyndromic cleft palate"	1	1	0	50
"1204"	"Nucleus accumbens volume"	1	0	1	100
"1205"	"Number of decayed, missing and filled tooth surfaces or use of dentures"	4	3	1	57.1428571428571
"1206"	"Number of sexual partners"	2	0	2	100
"1207"	"Number of twin births"	1	0	1	100
"1208"	"Obese vs. thin"	1	1	0	50
"1209"	"Obesity"	52	29	23	64.1975308641975
"1210"	"Obesity-related traits"	70	54	16	56.4516129032258
"1211"	"Obesity (early onset extreme)"	12	6	6	66.6666666666667
"1212"	"Obesity (extreme)"	8	5	3	61.5384615384615
"1213"	"Objective response to lithium treatment in bipolar disorder"	1	1	0	50
"1214"	"Obsessive-compulsive symptoms"	1	0	1	100
"1215"	"Obstetric antiphospholipid syndrome"	1	0	1	100
"1216"	"Obstructive sleep apnea trait (apnea hypopnea index, change over time)"	1	0	1	100
"1217"	"Offspring birth weight"	20	9	11	68.9655172413793
"1218"	"Oleic acid (18:1n-9) levels"	6	4	2	60
"1219"	"Opioid dependence"	1	0	1	100
"1220"	"Opioid exposure"	2	0	2	100
"1221"	"Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder"	1	0	1	100
"1222"	"Optic cup area"	35	23	12	60.3448275862069
"1223"	"Optic disc area"	32	28	4	53.3333333333333
"1224"	"Optic disc parameters"	2	1	1	66.6666666666667
"1225"	"Optic disc radius"	1	1	0	50
"1226"	"Optic disc size"	10	7	3	58.8235294117647
"1227"	"Optic nerve head parameters (multi-trait analysis)"	2	1	1	66.6666666666667
"1228"	"Optic nerve measurement (cup area)"	4	2	2	66.6666666666667
"1229"	"Optic nerve measurement (disc area)"	5	3	2	62.5
"1230"	"Optic nerve measurement (rim area)"	2	2	0	50
"1231"	"Oral cavity and pharyngeal cancer"	2	2	0	50
"1232"	"Orofacial clefts"	10	8	2	55.5555555555556
"1233"	"Ossification of the posterior longitudinal ligament of the spine"	2	0	2	100
"1234"	"Osteoarthritis"	4	1	3	80
"1235"	"Osteoarthritis (hand, severe)"	1	1	0	50
"1236"	"Osteoarthritis (hip)"	4	1	3	80
"1237"	"Osteoarthritis biomarkers"	1	0	1	100
"1238"	"Osteoarthritis of the hip or knee"	1	1	0	50
"1239"	"Osteoarthritis of the knee (with total joint replacement)"	1	0	1	100
"1240"	"Osteolysis in total hip arthroplasty (time to prosthesis revision)"	1	1	0	50
"1241"	"Osteoporosis"	1	1	0	50
"1242"	"Osteoporosis-related phenotypes"	1	1	0	50
"1243"	"Osteoprotegerin levels"	3	0	3	100
"1244"	"Osteosarcoma"	1	1	0	50
"1245"	"Other erythrocyte phenotypes"	2	2	0	50
"1246"	"Ovarian cancer"	10	7	3	58.8235294117647
"1247"	"Ovarian cancer in BRCA1 mutation carriers"	4	2	2	66.6666666666667
"1248"	"Ovarian clear cell cancer"	1	0	1	100
"1249"	"Overweight status"	1	0	1	100
"1250"	"P wave duration"	2	2	0	50
"1251"	"Paget's disease"	6	3	3	66.6666666666667
"1252"	"Pain"	1	0	1	100
"1253"	"Pallidum volume"	2	0	2	100
"1254"	"Palmitic acid (16:0) levels"	4	3	1	57.1428571428571
"1255"	"Palmitoleic acid (16:1n-7) levels"	5	3	2	62.5
"1256"	"Pancreatic cancer"	25	11	14	69.4444444444444
"1257"	"Pancreatic ductal adenocarcinoma"	1	0	1	100
"1258"	"Pancreatitis"	2	2	0	50
"1259"	"Panic disorder"	1	1	0	50
"1260"	"Pappalysin-1 levels"	1	1	0	50
"1261"	"Parent of origin effect on language impairment (paternal)"	1	1	0	50
"1262"	"Parent of origin effect on receptive language ability (paternal)"	1	0	1	100
"1263"	"Parental lifespan"	3	2	1	60
"1264"	"Parental longevity (both parents in top 10%)"	3	1	2	75
"1265"	"Parental longevity (combined parental age at death)"	1	0	1	100
"1266"	"Parental longevity (combined parental attained age, Martingale residuals)"	12	5	7	70.5882352941176
"1267"	"Parental longevity (father's age at death or father's attained age)"	8	2	6	80
"1268"	"Parental longevity (father's age at death)"	4	2	2	66.6666666666667
"1269"	"Parental longevity (father's attained age)"	4	1	3	80
"1270"	"Parental longevity (mother's age at death or mother's attained age)"	6	2	4	75
"1271"	"Parental longevity (mother's age at death)"	5	2	3	71.4285714285714
"1272"	"Parental longevity (mother's attained age)"	1	0	1	100
"1273"	"Parkinson's disease"	41	17	24	70.6896551724138
"1274"	"Parkinson's disease or first degree relation to individual with Parkinson's disease"	5	2	3	71.4285714285714
"1275"	"PCA3 expression level"	1	1	0	50
"1276"	"Peak expiratory flow"	16	11	5	59.2592592592593
"1277"	"Peak hip bone mineral content"	1	1	0	50
"1278"	"Peak insulin response"	2	1	1	66.6666666666667
"1279"	"Peanut allergy"	1	1	0	50
"1280"	"Pediatric autoimmune diseases"	6	6	0	50
"1281"	"Pediatric bone mineral content (spine)"	2	2	0	50
"1282"	"Pediatric bone mineral density (femoral neck)"	1	1	0	50
"1283"	"Pediatric bone mineral density (hip)"	1	1	0	50
"1284"	"Pediatric bone mineral density (spine)"	2	2	0	50
"1285"	"Pediatric non-alcoholic fatty liver disease activity score"	2	1	1	66.6666666666667
"1286"	"PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia"	1	1	0	50
"1287"	"Pelvic organ prolapse"	3	2	1	60
"1288"	"Pelvic organ prolapse (moderate/severe)"	1	0	1	100
"1289"	"Pemphigus"	1	1	0	50
"1290"	"Pemphigus vulgaris"	2	1	1	66.6666666666667
"1291"	"Pepsinogen I/II ratio"	1	1	0	50
"1292"	"Perceived intensity of glucose"	1	0	1	100
"1293"	"Perceived unattractiveness to mosquitoes"	2	2	0	50
"1294"	"Percentage gas trapping"	4	3	1	57.1428571428571
"1295"	"Periodontal microbiota"	6	2	4	75
"1296"	"Periodontitis"	1	1	0	50
"1297"	"Periodontitis (CDC/AAP)"	4	1	3	80
"1298"	"Periodontitis (DPAL)"	2	1	1	66.6666666666667
"1299"	"Periodontitis (Mean PAL)"	2	1	1	66.6666666666667
"1300"	"Periodontitis (PAL4Q3)"	1	0	1	100
"1301"	"Peripheral arterial disease (traffic-related air pollution interaction)"	2	1	1	66.6666666666667
"1302"	"Peripheral artery disease"	6	4	2	60
"1303"	"Periventricular white matter hyperintensities"	1	0	1	100
"1304"	"Permanent tooth development"	3	1	2	75
"1305"	"Personality dimensions"	6	4	2	60
"1306"	"Phoneme awareness"	1	1	0	50
"1307"	"Phosphatidylcholine-ether levels"	1	1	0	50
"1308"	"Phosphatidylcholine levels"	4	4	0	50
"1309"	"Phosphatidylethanolamine-ether levels"	2	2	0	50
"1310"	"Phosphatidylethanolamine levels"	1	1	0	50
"1311"	"Phosphatidylinositol levels"	5	0	5	100
"1312"	"Phosphorus levels"	2	2	0	50
"1313"	"Photic sneeze reflex"	1	0	1	100
"1314"	"Phytosterol levels"	1	1	0	50
"1315"	"Pit-and-Fissure caries"	4	3	1	57.1428571428571
"1316"	"Placental abruption"	2	0	2	100
"1317"	"Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer"	1	0	1	100
"1318"	"Plasma anti-thyroglobulin levels"	1	0	1	100
"1319"	"Plasma clozapine levels in treatment-resistant schizophrenia"	1	1	0	50
"1320"	"Plasma free amino acid levels"	6	2	4	75
"1321"	"Plasma free amino acid levels (adjusted for twenty other PFAAs)"	6	1	5	85.7142857142857
"1322"	"Plasma homocysteine levels (post-methionine load test)"	3	2	1	60
"1323"	"Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)"	10	9	1	52.6315789473684
"1324"	"Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)"	12	9	3	57.1428571428571
"1325"	"Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)"	2	1	1	66.6666666666667
"1326"	"Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)"	12	10	2	54.5454545454545
"1327"	"Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)"	1	1	0	50
"1328"	"Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)"	8	8	0	50
"1329"	"Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)"	6	6	0	50
"1330"	"Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)"	5	4	1	55.5555555555556
"1331"	"Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)"	7	6	1	53.8461538461539
"1332"	"Plasma parathyroid hormone levels"	1	1	0	50
"1333"	"Plasma plasminogen activator levels"	3	1	2	75
"1334"	"Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease"	2	2	0	50
"1335"	"Plasma renin activity levels"	1	1	0	50
"1336"	"Plasma t-tau levels"	1	1	0	50
"1337"	"Plasma thyroid-stimulating hormone levels"	1	0	1	100
"1338"	"Platelet-derived growth factor BB levels"	2	1	1	66.6666666666667
"1339"	"Platelet-derived growth factor subunit B levels"	2	0	2	100
"1340"	"Platelet aggregation"	18	16	2	52.9411764705882
"1341"	"Platelet count"	196	110	86	64.0522875816993
"1342"	"Platelet distribution width"	32	19	13	62.7450980392157
"1343"	"Platelet endothelial cell adhesion molecule levels"	1	1	0	50
"1344"	"Plateletcrit"	51	35	16	59.3023255813953
"1345"	"Pneumoconiosis in silica exposure"	1	1	0	50
"1346"	"Polycystic ovary syndrome"	15	6	9	71.4285714285714
"1347"	"Poor prognosis in Crohn's disease"	1	1	0	50
"1348"	"Positive affect"	5	4	1	55.5555555555556
"1349"	"Post bronchodilator FEV1"	47	25	22	65.2777777777778
"1350"	"Post bronchodilator FEV1 in COPD"	2	0	2	100
"1351"	"Post bronchodilator FEV1/FVC ratio"	53	28	25	65.4320987654321
"1352"	"Post bronchodilator FEV1/FVC ratio in COPD"	21	13	8	61.7647058823529
"1353"	"Post bronchodilator percent predicted FEV1 in smoking"	1	1	0	50
"1354"	"Postburn scar height"	2	1	1	66.6666666666667
"1355"	"Postprandial triglyceride levels"	2	0	2	100
"1356"	"Postprandial triglyceride response to high fat diet meal"	2	1	1	66.6666666666667
"1357"	"PR interval"	45	32	13	58.4415584415584
"1358"	"PR segment"	4	3	1	57.1428571428571
"1359"	"Pre-treatment viral load in HIV-1 infection"	3	2	1	60
"1360"	"Predicted suicide risk"	1	0	1	100
"1361"	"Predicted visceral adipose tissue"	11	10	1	52.3809523809524
"1362"	"Preeclampsia (maternal genotype effect)"	1	0	1	100
"1363"	"Preschool internalizing problems"	1	0	1	100
"1364"	"Preterm birth (maternal effect)"	1	1	0	50
"1365"	"Prevalent atrial fibrillation"	1	0	1	100
"1366"	"Primary biliary cholangitis"	34	26	8	56.6666666666667
"1367"	"Primary biliary cirrhosis"	5	3	2	62.5
"1368"	"Primary central nervous system lymphoma"	1	0	1	100
"1369"	"Primary sclerosing cholangitis"	9	7	2	56.25
"1370"	"Primary tooth development (number of teeth)"	10	6	4	62.5
"1371"	"Primary tooth development (time to first tooth eruption)"	14	8	6	63.6363636363636
"1372"	"Problematic alcohol use"	1	1	0	50
"1373"	"Problematic alcohol use (MTAG)"	3	1	2	75
"1374"	"Progranulin levels"	1	0	1	100
"1375"	"Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)"	1	0	1	100
"1376"	"Progression free survival in metastatic colorectal cancer (chemotherapy interaction)"	1	1	0	50
"1377"	"Progressive supranuclear palsy"	1	1	0	50
"1378"	"Proheparin-binding EGF-like growth factor levels"	1	1	0	50
"1379"	"Proinsulin levels"	5	1	4	83.3333333333333
"1380"	"Proportion of activated microglia (midfrontal cortex)"	1	0	1	100
"1381"	"Prostate-specific antigen levels"	12	4	8	75
"1382"	"Prostate-specific antigen levels (conditioned on lead SNPs)"	1	0	1	100
"1383"	"Prostate cancer"	214	96	118	69.0322580645161
"1384"	"Prostate cancer (advanced)"	4	3	1	57.1428571428571
"1385"	"Prostate cancer (early onset)"	4	2	2	66.6666666666667
"1386"	"Prostate cancer aggressiveness"	1	0	1	100
"1387"	"Protein C levels"	4	3	1	57.1428571428571
"1388"	"Prothrombin time"	1	1	0	50
"1389"	"Psoriasis"	77	47	30	62.0967741935484
"1390"	"Psoriasis vulgaris"	12	7	5	63.1578947368421
"1391"	"Psoriatic arthritis"	2	1	1	66.6666666666667
"1392"	"Psychosis (methamphetamine induced)"	1	0	1	100
"1393"	"Pubertal anthropometrics"	10	4	6	71.4285714285714
"1394"	"Puberty onset (genital enlargement)"	1	1	0	50
"1395"	"Pulmonary arterial hypertension"	1	1	0	50
"1396"	"Pulmonary emphysema"	3	1	2	75
"1397"	"Pulmonary function"	21	12	9	63.6363636363636
"1398"	"Pulmonary function (smoking interaction)"	19	7	12	73.0769230769231
"1399"	"Pulmonary function in asthmatics"	3	1	2	75
"1400"	"Pulse pressure"	112	50	62	69.1358024691358
"1401"	"Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)"	1	1	0	50
"1402"	"Pulse pressure x alcohol consumption interaction (2df test)"	3	3	0	50
"1403"	"Pursuit maintenance gain"	4	3	1	57.1428571428571
"1404"	"Putamen volume"	3	1	2	75
"1405"	"QRS duration"	51	41	10	55.4347826086957
"1406"	"QT dynamics during exercise"	3	0	3	100
"1407"	"QT dynamics during recovery from exercise"	1	0	1	100
"1408"	"QT interval"	53	37	16	58.8888888888889
"1409"	"QT interval (ambient particulate matter interaction)"	1	0	1	100
"1410"	"QT interval (drug interaction)"	6	4	2	60
"1411"	"Quantitative traits"	11	3	8	78.5714285714286
"1412"	"Random C-peptide levels in type I diabetes"	1	1	0	50
"1413"	"Rapid alternating stimulus test for letters/numbers"	1	1	0	50
"1414"	"Rapid automised naming and rapid alternating stimulus test performance"	1	1	0	50
"1415"	"Rapid automised naming of digits"	2	0	2	100
"1416"	"Rapid automised naming of letters"	4	2	2	66.6666666666667
"1417"	"Rapid automised naming of pictures"	3	0	3	100
"1418"	"Rate of cognitive decline in Alzheimer's disease"	15	0	15	100
"1419"	"Rate of cognitive decline in mild cognitive impairment (time interaction)"	1	1	0	50
"1420"	"Rate of ventricular enlargement"	1	1	0	50
"1421"	"Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy)"	1	1	0	50
"1422"	"Recalcitrant atopic dermatitis"	1	1	0	50
"1423"	"Receptor for advanced glycosylation end products levels"	1	1	0	50
"1424"	"Rectal cancer"	2	2	0	50
"1425"	"Recurrence of Clostridium difficile infection x bezlotuxumab treatment interaction (2df test)"	1	1	0	50
"1426"	"Recurrent major depressive disorder"	2	1	1	66.6666666666667
"1427"	"Red blood cell count"	126	79	47	61.4634146341463
"1428"	"Red blood cell traits"	37	27	10	57.8125
"1429"	"Red cell distribution width"	99	51	48	66
"1430"	"Red vs. brown/black hair color"	2	2	0	50
"1431"	"Refractive astigmatism"	7	2	5	77.7777777777778
"1432"	"Refractive error"	13	9	4	59.0909090909091
"1433"	"Refractory celiac disease type II"	1	1	0	50
"1434"	"Renal cell carcinoma"	4	3	1	57.1428571428571
"1435"	"Renal function-related traits (BUN)"	8	5	3	61.5384615384615
"1436"	"Renal function-related traits (eGRFcrea)"	4	3	1	57.1428571428571
"1437"	"Renal function-related traits (sCR)"	4	3	1	57.1428571428571
"1438"	"Renal function-related traits (urea)"	3	2	1	60
"1439"	"Renal function and chronic kidney disease"	2	1	1	66.6666666666667
"1440"	"Renal overload gout"	1	1	0	50
"1441"	"Renal sinus fat"	2	1	1	66.6666666666667
"1442"	"Renal underexcretion gout"	5	2	3	71.4285714285714
"1443"	"Resistance to antihypertensive treatment in hypertension"	1	0	1	100
"1444"	"Resistant hypertension"	2	2	0	50
"1445"	"Resistin levels"	5	5	0	50
"1446"	"Response to alcohol consumption (flushing response)"	1	0	1	100
"1447"	"Response to angiotensin II receptor blocker therapy"	1	1	0	50
"1448"	"Response to anti-depressant treatment in major depressive disorder"	2	1	1	66.6666666666667
"1449"	"Response to antidepressants"	1	1	0	50
"1450"	"Response to antineoplastic agents"	2	2	0	50
"1451"	"Response to antipsychotic treatment"	2	2	0	50
"1452"	"Response to bleomycin (chromatid breaks)"	2	2	0	50
"1453"	"Response to citalopram treatment"	4	2	2	66.6666666666667
"1454"	"Response to cognitive-behavioural therapy in anxiety disorder"	1	1	0	50
"1455"	"Response to Dalcetrapib treatment in acute coronary syndrome"	1	0	1	100
"1456"	"Response to diuretic therapy in hypertension"	1	0	1	100
"1457"	"Response to exercise (triglyceride level interaction)"	1	0	1	100
"1458"	"Response to fenofibrate"	2	2	0	50
"1459"	"Response to haloperidol in schizophrenia"	1	1	0	50
"1460"	"Response to hepatitis C treatment"	9	6	3	60
"1461"	"Response to iloperidone treatment (QT prolongation)"	3	1	2	75
"1462"	"Response to interferon beta therapy"	1	0	1	100
"1463"	"Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer"	1	1	0	50
"1464"	"Response to irinotecan in non-small-cell lung cancer"	1	1	0	50
"1465"	"Response to ketamine in bipolar disorder or major depression (dissociation effects)"	2	0	2	100
"1466"	"Response to lithium treatment in bipolar disorder"	1	0	1	100
"1467"	"Response to methotrexate in rheumatoid arthritis"	1	0	1	100
"1468"	"Response to montelukast in asthma (change in FEV1)"	2	1	1	66.6666666666667
"1469"	"Response to olanzapine in schizophrenia"	1	1	0	50
"1470"	"Response to opioid analgesics in cancer (pain decrease)"	1	1	0	50
"1471"	"Response to paliperidone in schizophrenia (CGI-S score)"	1	0	1	100
"1472"	"Response to paliperidone in schizophrenia (negative Marder score)"	5	1	4	83.3333333333333
"1473"	"Response to paliperidone in schizophrenia (PANSS score)"	3	0	3	100
"1474"	"Response to paliperidone in schizophrenia (positive Marder score)"	5	0	5	100
"1475"	"Response to perphenazine in schizophrenia"	1	0	1	100
"1476"	"Response to platinum-based chemotherapy in non-small-cell lung cancer"	1	0	1	100
"1477"	"Response to quetiapine in schizophrenia"	2	2	0	50
"1478"	"Response to radiotherapy in prostate cancer (overall toxicity)"	1	1	0	50
"1479"	"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)"	1	1	0	50
"1480"	"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)"	2	1	1	66.6666666666667
"1481"	"Response to risperidone in schizophrenia"	1	1	0	50
"1482"	"Response to simvastatin treatment (PCSK9 protein level change)"	1	1	0	50
"1483"	"Response to statin therapy"	6	5	1	54.5454545454545
"1484"	"Response to statins (LDL cholesterol change)"	4	4	0	50
"1485"	"Response to statins (LDL cholesterol percent change)"	2	2	0	50
"1486"	"Response to tamoxifen in breast cancer"	1	1	0	50
"1487"	"Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer"	1	0	1	100
"1488"	"Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)"	1	1	0	50
"1489"	"Response to TNF antagonist treatment"	4	3	1	57.1428571428571
"1490"	"Resting-state electroencephalogram vigilance"	2	1	1	66.6666666666667
"1491"	"Resting heart rate"	18	9	9	66.6666666666667
"1492"	"Resting metabolic rate"	1	1	0	50
"1493"	"Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)"	1	0	1	100
"1494"	"Restless legs syndrome"	7	3	4	70
"1495"	"Reticulocyte count"	40	24	16	62.5
"1496"	"Reticulocyte fraction of red cells"	39	21	18	65
"1497"	"Retinal arteriolar caliber"	2	0	2	100
"1498"	"Retinal vascular caliber"	2	2	0	50
"1499"	"Retinol levels"	1	1	0	50
"1500"	"Retinopathy in non-diabetics"	1	1	0	50
"1501"	"Retinopathy x type 2 diabetes interaction"	1	0	1	100
"1502"	"Rheumatoid arthritis"	201	121	80	62.4223602484472
"1503"	"Rheumatoid arthritis (ACPA-positive)"	15	10	5	60
"1504"	"Right-sided colonic diverticulosis"	1	0	1	100
"1505"	"Risk-taking tendency (4-domain principal component model)"	3	2	1	60
"1506"	"Rosacea symptom severity"	11	2	9	84.6153846153846
"1507"	"RR interval (heart rate)"	3	2	1	60
"1508"	"Sagittal craniosynostosis"	2	2	0	50
"1509"	"Salivary metabolite levels"	1	1	0	50
"1510"	"Sarcoidosis"	1	0	1	100
"1511"	"Schizophrenia"	271	143	128	65.4589371980676
"1512"	"Schizophrenia, bipolar disorder and depression (combined)"	1	1	0	50
"1513"	"Sclerosing cholangitis and ulcerative colitis (combined)"	2	1	1	66.6666666666667
"1514"	"Seasonality"	1	0	1	100
"1515"	"Self-rated health"	2	1	1	66.6666666666667
"1516"	"Self-reported allergy"	10	9	1	52.6315789473684
"1517"	"Self-reported math ability"	29	13	16	69.0476190476191
"1518"	"Self-reported math ability (MTAG)"	35	22	13	61.4035087719298
"1519"	"Self-reported risk-taking behaviour"	4	0	4	100
"1520"	"Sense of smell"	1	0	1	100
"1521"	"Serous borderline ovarian cancer"	2	2	0	50
"1522"	"Serous invasive ovarian cancer"	3	2	1	60
"1523"	"Serum 25-Hydroxyvitamin D levels"	28	11	17	71.7948717948718
"1524"	"Serum albumin level"	3	3	0	50
"1525"	"Serum alkaline phosphatase levels"	23	11	12	67.6470588235294
"1526"	"Serum alpha1-antitrypsin levels"	1	0	1	100
"1527"	"Serum bilirubin levels in metabolic syndrome"	5	5	0	50
"1528"	"Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome"	7	5	2	58.3333333333333
"1529"	"Serum cancer antigen 19.9 levels"	1	1	0	50
"1530"	"Serum carcinoembryonic antigen levels"	4	4	0	50
"1531"	"Serum creatinine levels"	1	0	1	100
"1532"	"Serum docosahexaenoic fatty acid concentration in metabolic syndrome"	1	1	0	50
"1533"	"Serum galactose-deficient IgA1 levels"	1	1	0	50
"1534"	"Serum immune biomarker levels"	3	0	3	100
"1535"	"Serum lipase activity"	1	1	0	50
"1536"	"Serum metabolite concentrations in chronic kidney disease"	10	9	1	52.6315789473684
"1537"	"Serum metabolite levels"	8	5	3	61.5384615384615
"1538"	"Serum metabolite ratios in chronic kidney disease"	86	85	1	50.2923976608187
"1539"	"Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome"	1	1	0	50
"1540"	"Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome"	2	1	1	66.6666666666667
"1541"	"Serum oxytocin levels"	1	1	0	50
"1542"	"Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome"	1	1	0	50
"1543"	"Serum prostate-specific antigen levels"	5	1	4	83.3333333333333
"1544"	"Serum protein levels (sST2)"	2	1	1	66.6666666666667
"1545"	"Serum tamsulosin hydrochloride concentration"	3	0	3	100
"1546"	"Serum thyroid-stimulating hormone levels"	3	3	0	50
"1547"	"Serum total protein level"	3	2	1	60
"1548"	"Serum urea levels"	1	1	0	50
"1549"	"Serum uric acid levels"	32	16	16	66.6666666666667
"1550"	"Severe COVID-19 infection with respiratory failure (analysis I)"	1	1	0	50
"1551"	"Severe COVID-19 infection with respiratory failure (analysis II)"	1	1	0	50
"1552"	"Severity of nausea and vomiting of pregnancy"	1	0	1	100
"1553"	"Sex hormone-binding globulin levels"	115	51	64	69.2771084337349
"1554"	"Sex hormone-binding globulin levels adjusted for BMI"	102	43	59	70.3448275862069
"1555"	"Sex hormone levels"	2	2	0	50
"1556"	"Sexual dimorphism in anthropometric traits"	3	3	0	50
"1557"	"Sexual dysfunction (female)"	1	0	1	100
"1558"	"Shingles"	1	0	1	100
"1559"	"Short-term memory (digit-span task)"	1	0	1	100
"1560"	"Shoulder impingement syndrome"	2	0	2	100
"1561"	"Sickle cell anemia (haemolysis)"	1	0	1	100
"1562"	"Sitting height ratio"	8	1	7	88.8888888888889
"1563"	"Sj**gren's syndrome"	3	2	1	60
"1564"	"Skin aging (microtopography measurement)"	1	1	0	50
"1565"	"Skin colour saturation"	2	2	0	50
"1566"	"Skin pigmentation"	7	6	1	53.8461538461539
"1567"	"Skin reflectance (Melanin index)"	2	2	0	50
"1568"	"Skin sensitivity to sun"	1	1	0	50
"1569"	"Sleep (number of episodes)"	1	1	0	50
"1570"	"Sleep duration"	7	5	2	58.3333333333333
"1571"	"Sleep duration (oversleepers vs undersleepers)"	1	1	0	50
"1572"	"Sleep duration (short sleep)"	1	1	0	50
"1573"	"Small vessel stroke"	2	2	0	50
"1574"	"Smoking behavior"	8	5	3	61.5384615384615
"1575"	"Smoking behaviour (cigarette pack-years)"	3	3	0	50
"1576"	"Smoking behaviour (cigarettes smoked per day)"	12	9	3	57.1428571428571
"1577"	"Smoking cessation"	4	3	1	57.1428571428571
"1578"	"Smoking cessation (MTAG)"	5	4	1	55.5555555555556
"1579"	"Smoking initiation"	7	5	2	58.3333333333333
"1580"	"Smoking initiation (ever regular vs never regular)"	26	20	6	56.5217391304348
"1581"	"Smoking initiation (ever regular vs never regular) (MTAG)"	39	28	11	58.2089552238806
"1582"	"Smoking status (ever vs never smokers)"	16	9	7	64
"1583"	"Smooth-surface caries"	6	0	6	100
"1584"	"Snoring"	11	1	10	91.6666666666667
"1585"	"Soluble E-selectin levels"	1	1	0	50
"1586"	"Soluble gp130 levels"	1	0	1	100
"1587"	"Soluble ICAM-1"	5	2	3	71.4285714285714
"1588"	"Soluble levels of adhesion molecules"	2	1	1	66.6666666666667
"1589"	"Spatial processing"	1	1	0	50
"1590"	"Speech perception in dyslexia"	2	2	0	50
"1591"	"Spherical equivalent"	28	13	15	68.2926829268293
"1592"	"Spherical equivalent (joint analysis main effects and education interaction)"	12	8	4	60
"1593"	"Spherical equivalent or myopia (age of diagnosis)"	19	12	7	61.2903225806452
"1594"	"Sphingolipid levels"	8	8	0	50
"1595"	"Sphingomyelin levels"	1	1	0	50
"1596"	"Spine bone size"	3	3	0	50
"1597"	"Spontaneous adipocyte lipolysis"	2	0	2	100
"1598"	"Spontaneous coronary artery dissection"	6	6	0	50
"1599"	"Spontaneous dizygotic twinning"	1	0	1	100
"1600"	"Sporadic neuroblastoma"	1	1	0	50
"1601"	"Squamous cell carcinoma"	6	5	1	54.5454545454545
"1602"	"Squamous cell lung carcinoma"	6	3	3	66.6666666666667
"1603"	"ST2 protein levels"	2	1	1	66.6666666666667
"1604"	"Stearic acid (18:0) levels"	6	2	4	75
"1605"	"Stem cell factor levels"	6	5	1	54.5454545454545
"1606"	"Stem cell growth factor beta levels"	1	0	1	100
"1607"	"Stimulated adipocyte lipolysis"	2	1	1	66.6666666666667
"1608"	"Stress sensitivity (neuroticism score x major depressive disorder status interaction)"	2	1	1	66.6666666666667
"1609"	"Stroke"	1	1	0	50
"1610"	"Stroke (ischemic)"	4	1	3	80
"1611"	"Stromal-cell-derived factor 1 alpha levels"	2	0	2	100
"1612"	"Subcortical brain region volumes"	6	2	4	75
"1613"	"Subcutaneous adipose tissue"	11	6	5	64.7058823529412
"1614"	"Subjective response to lithium treatment"	1	1	0	50
"1615"	"Subjective well-being"	6	3	3	66.6666666666667
"1616"	"Subjective well-being (MTAG)"	4	2	2	66.6666666666667
"1617"	"Sucrose liking"	1	0	1	100
"1618"	"Suffering from nerves"	1	0	1	100
"1619"	"Suicidal ideation"	2	0	2	100
"1620"	"Suicidal ideation in depression or bipolar disorder"	1	1	0	50
"1621"	"Suicidal or self-harm ideation"	1	1	0	50
"1622"	"Suicide attempts"	1	0	1	100
"1623"	"Suicide attempts in bipolar disorder or schizophrenia"	1	0	1	100
"1624"	"Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia"	6	0	6	100
"1625"	"Suicide ideation score in major depressive disorder"	1	1	0	50
"1626"	"Sum basophil neutrophil counts"	13	8	5	61.9047619047619
"1627"	"Sum eosinophil basophil counts"	6	5	1	54.5454545454545
"1628"	"Sum neutrophil eosinophil counts"	13	9	4	59.0909090909091
"1629"	"Sunburns"	2	1	1	66.6666666666667
"1630"	"Superior frontal gyrus grey matter volume"	2	0	2	100
"1631"	"Survival in pancreatic cancer"	6	2	4	75
"1632"	"Susceptibility to persistent hepatitis B virus infection"	2	2	0	50
"1633"	"Sweet beverage consumption"	2	2	0	50
"1634"	"Sweet taste perception in obesity with metabolic syndrome"	1	0	1	100
"1635"	"Sweet taste preference"	1	1	0	50
"1636"	"Systemic lupus erythematosus"	65	51	14	56.0344827586207
"1637"	"Systemic sclerosis"	7	6	1	53.8461538461539
"1638"	"Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)"	3	3	0	50
"1639"	"Systolic blood pressure"	198	112	86	63.8709677419355
"1640"	"Systolic blood pressure (long-term average)"	1	0	1	100
"1641"	"Systolic blood pressure change trajectories"	1	1	0	50
"1642"	"Systolic blood pressure response to hydrochlorothiazide in hypertension"	1	1	0	50
"1643"	"Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)"	4	1	3	80
"1644"	"Systolic blood pressure x alcohol consumption interaction (2df test)"	8	4	4	66.6666666666667
"1645"	"Systolic blood pressure x quantitative lifestyle risk score interaction (2df test)"	1	0	1	100
"1646"	"T-Cell Immunoglobulin and Mucin domain 1 levels"	1	1	0	50
"1647"	"T wave morphology restitution during exercise"	1	0	1	100
"1648"	"T wave morphology restitution during exercise (MTAG)"	1	0	1	100
"1649"	"T wave morphology restitution during recovery from exercise"	1	0	1	100
"1650"	"T wave morphology restitution during recovery from exercise (MTAG)"	1	0	1	100
"1651"	"Takayasu arteritis"	2	1	1	66.6666666666667
"1652"	"Tanning"	6	3	3	66.6666666666667
"1653"	"Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome"	1	1	0	50
"1654"	"Taxane-induced peripheral neuropathy in breast cancer"	1	1	0	50
"1655"	"TB-LM or TBLH-BMD (pleiotropy)"	3	3	0	50
"1656"	"Tea consumption"	7	4	3	63.6363636363636
"1657"	"Telomere length"	9	7	2	56.25
"1658"	"Temperament"	6	4	2	60
"1659"	"Testicular cancer"	3	1	2	75
"1660"	"Testicular germ cell cancer"	2	1	1	66.6666666666667
"1661"	"Testicular germ cell tumor"	51	36	15	58.6206896551724
"1662"	"Testosterone levels"	1	1	0	50
"1663"	"Tetralogy of Fallot"	4	3	1	57.1428571428571
"1664"	"Thiazide-induced adverse metabolic effects in hypertensive patients"	9	6	3	60
"1665"	"Thiopurine-induced leukopenia in inflammatory bowel disease"	1	0	1	100
"1666"	"Thyroid cancer"	8	8	0	50
"1667"	"Thyroid cancer (Papillary, radiation-related)"	1	1	0	50
"1668"	"Thyroid function"	2	0	2	100
"1669"	"Thyroid hormone levels"	36	24	12	60
"1670"	"Thyroid peroxidase antibody levels"	4	3	1	57.1428571428571
"1671"	"Thyroid peroxidase antibody positivity"	2	2	0	50
"1672"	"Thyroid stimulating hormone levels"	9	6	3	60
"1673"	"Thyroid volume"	5	1	4	83.3333333333333
"1674"	"Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor"	2	0	2	100
"1675"	"Time to smoke first cigarette in the morning"	1	0	1	100
"1676"	"Tissue factor levels"	2	2	0	50
"1677"	"TNF-related apoptosis-inducing ligand receptor 2 levels"	1	0	1	100
"1678"	"Toenail selenium levels"	4	2	2	66.6666666666667
"1679"	"Tonsillectomy"	3	3	0	50
"1680"	"Total bilirubin levels in HIV-1 infection"	1	1	0	50
"1681"	"Total body bone mineral density"	19	6	13	76
"1682"	"Total body bone mineral density (age 0-15)"	1	0	1	100
"1683"	"Total body bone mineral density (age 30-45)"	1	0	1	100
"1684"	"Total body bone mineral density (age 45-60)"	4	1	3	80
"1685"	"Total body bone mineral density (age over 60)"	5	3	2	62.5
"1686"	"Total body bone mineral density (MTAG)"	1	1	0	50
"1687"	"Total cholesterol levels"	381	191	190	66.6083916083916
"1688"	"Total testosterone levels"	65	23	42	73.8636363636364
"1689"	"Total triglycerides levels"	4	1	3	80
"1690"	"Tourette syndrome"	4	4	0	50
"1691"	"TPE interval (resting)"	8	4	4	66.6666666666667
"1692"	"TRAIL levels"	4	0	4	100
"1693"	"Trans fatty acid levels"	41	33	8	55.4054054054054
"1694"	"Trauma exposure"	4	1	3	80
"1695"	"Trauma exposure in major depressive disorder-negative individuals"	2	1	1	66.6666666666667
"1696"	"Triacylglyceride levels"	8	0	8	100
"1697"	"Triglyceride levels"	146	66	80	68.8679245283019
"1698"	"Triglyceride levels in current drinkers"	30	12	18	71.4285714285714
"1699"	"Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)"	35	17	18	67.3076923076923
"1700"	"Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)"	32	13	19	71.1111111111111
"1701"	"Triglycerides"	363	176	187	67.3469387755102
"1702"	"Triglycerides x physical activity interaction (2df test)"	3	1	2	75
"1703"	"Trochanter size"	2	2	0	50
"1704"	"Trunk fat mass"	2	0	2	100
"1705"	"Tuberculosis"	5	1	4	83.3333333333333
"1706"	"Tumor biomarkers"	2	1	1	66.6666666666667
"1707"	"Tumor necrosis factor alpha levels"	1	0	1	100
"1708"	"Tumor necrosis factor beta levels"	2	1	1	66.6666666666667
"1709"	"Tumor necrosis factor levels"	2	1	1	66.6666666666667
"1710"	"Tumor necrosis factor receptor 2 levels"	2	2	0	50
"1711"	"Tumor necrosis factor receptor superfamily member 5 levels"	1	1	0	50
"1712"	"Tumor necrosis factor receptor superfamily member 6 levels"	1	1	0	50
"1713"	"Two-hour glucose challenge"	2	1	1	66.6666666666667
"1714"	"Type 1 diabetes"	50	32	18	60.9756097560976
"1715"	"Type 1 diabetes and autoimmune thyroid diseases"	2	2	0	50
"1716"	"Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)"	2	2	0	50
"1717"	"Type 1 diabetes nephropathy"	4	3	1	57.1428571428571
"1718"	"Type 2 diabetes"	557	272	285	67.189384800965
"1719"	"Type 2 diabetes (adjusted for BMI)"	31	13	18	70.4545454545455
"1720"	"Type 2 diabetes nephropathy"	2	0	2	100
"1721"	"Ulcerative colitis"	91	49	42	65
"1722"	"Ulcerative colitis or Crohn's disease"	1	0	1	100
"1723"	"Ultradistal forearm bone mineral density"	1	1	0	50
"1724"	"Upper eyelid morphology"	1	1	0	50
"1725"	"Upper eyelid sagging severity"	1	1	0	50
"1726"	"Urate levels"	147	76	71	65.9192825112108
"1727"	"Urate levels (BMI interaction)"	8	3	5	72.7272727272727
"1728"	"Urate levels in lean individuals"	6	4	2	60
"1729"	"Urate levels in obese individuals"	3	1	2	75
"1730"	"Urate levels in overweight individuals"	11	6	5	64.7058823529412
"1731"	"Uric acid levels"	10	5	5	66.6666666666667
"1732"	"Urinary albumin-to-creatinine ratio"	22	13	9	62.8571428571429
"1733"	"Urinary albumin-to-creatinine ratio in non-diabetics"	3	3	0	50
"1734"	"Urinary albumin excretion"	5	3	2	62.5
"1735"	"Urinary albumin excretion (no hypertensive medication)"	3	2	1	60
"1736"	"Urinary bladder cancer"	4	1	3	80
"1737"	"Urinary electrolytes (magnesium/calcium ratio)"	1	1	0	50
"1738"	"Urinary magnesium excretion"	1	1	0	50
"1739"	"Urinary metabolite levels in chronic kidney disease"	27	10	17	72.972972972973
"1740"	"Urinary metabolite modules (eigenmetabolites) in chronic kidney disease"	6	1	5	85.7142857142857
"1741"	"Urinary metabolite ratios in chronic kidney disease"	7	7	0	50
"1742"	"Urinary metabolites"	3	1	2	75
"1743"	"Urinary metabolites (H-NMR features)"	35	10	25	77.7777777777778
"1744"	"Urinary potassium excretion"	2	2	0	50
"1745"	"Urinary potassium to creatinine ratio"	1	0	1	100
"1746"	"Urinary sodium excretion"	8	5	3	61.5384615384615
"1747"	"Urinary sodium to creatinine ratio"	2	0	2	100
"1748"	"Urinary sodium to potassium ratio"	1	0	1	100
"1749"	"Urinary uromodulin levels"	1	0	1	100
"1750"	"Urine pH measurement"	1	1	0	50
"1751"	"Urokinase plasminogen activator surface receptor levels"	1	0	1	100
"1752"	"Urolithiasis"	1	1	0	50
"1753"	"Uterine fibroid size (maximum volume)"	1	1	0	50
"1754"	"Uterine fibroids"	8	4	4	66.6666666666667
"1755"	"Uveal melanoma"	1	1	0	50
"1756"	"Uveal melanoma (TNM stage 3 or 4)"	1	1	0	50
"1757"	"Vaccenic acid (18:1n-7) levels"	2	2	0	50
"1758"	"Varicose veins"	4	1	3	80
"1759"	"Vascular dementia"	1	0	1	100
"1760"	"Vascular endothelial growth factor levels"	3	1	2	75
"1761"	"Vaspin levels"	1	1	0	50
"1762"	"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)"	1	1	0	50
"1763"	"Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)"	1	1	0	50
"1764"	"Venous thromboembolism"	19	16	3	54.2857142857143
"1765"	"Ventricular ectopy"	1	1	0	50
"1766"	"Verbal declarative memory"	8	3	5	72.7272727272727
"1767"	"Vertical cup-disc ratio"	24	20	4	54.5454545454545
"1768"	"Vertical cup-disc ratio (adjusted for vertical disc diameter)"	14	7	7	66.6666666666667
"1769"	"Vertical cup-disc ratio (multi-trait analysis)"	10	6	4	62.5
"1770"	"Very long-chain saturated fatty acid levels (fatty acid 20:0)"	4	1	3	80
"1771"	"Very long-chain saturated fatty acid levels (fatty acid 22:0)"	1	0	1	100
"1772"	"Very long-chain saturated fatty acid levels (fatty acid 24:0)"	2	0	2	100
"1773"	"Vigorous physical activity"	2	1	1	66.6666666666667
"1774"	"Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia"	1	1	0	50
"1775"	"Visceral adipose tissue adjusted for BMI"	14	9	5	60.8695652173913
"1776"	"Visceral adipose tissue/subcutaneous adipose tissue ratio"	14	12	2	53.8461538461539
"1777"	"Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI"	1	1	0	50
"1778"	"Visceral fat"	13	3	10	81.25
"1779"	"Vitamin B levels in ischemic stroke"	3	1	2	75
"1780"	"Vitamin B12 levels"	3	3	0	50
"1781"	"Vitamin D levels"	7	4	3	63.6363636363636
"1782"	"Vitamin D levels (dietary vitamin D intake interaction)"	1	0	1	100
"1783"	"Vitamin E levels"	1	1	0	50
"1784"	"Vitiligo"	25	17	8	59.5238095238095
"1785"	"Vogt-Koyanagi-Harada syndrome"	1	0	1	100
"1786"	"vWF and FVIII levels"	1	1	0	50
"1787"	"vWF levels"	1	1	0	50
"1788"	"vWF levels in ischaemic stroke and hyperhomocysteinaemia"	1	1	0	50
"1789"	"Waist-hip ratio"	187	103	84	64.4827586206897
"1790"	"Waist-to-hip circumference ratio (ever vs never smoking interaction)"	1	0	1	100
"1791"	"Waist-to-hip ratio adjusted for BMI"	108	56	52	65.8536585365854
"1792"	"Waist-to-hip ratio adjusted for BMI (additive genetic model)"	61	20	41	75.3086419753086
"1793"	"Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)"	62	32	30	65.9574468085106
"1794"	"Waist-to-hip ratio adjusted for BMI (age <50)"	5	3	2	62.5
"1795"	"Waist-to-hip ratio adjusted for BMI (age >50)"	8	6	2	57.1428571428571
"1796"	"Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)"	29	17	12	63.0434782608696
"1797"	"Waist-to-hip ratio adjusted for BMI in active individuals"	30	15	15	66.6666666666667
"1798"	"Waist-to-hip ratio adjusted for BMI in inactive individuals"	2	1	1	66.6666666666667
"1799"	"Waist-to-hip ratio adjusted for BMI in non-smokers"	24	16	8	60
"1800"	"Waist-to-hip ratio adjusted for BMI in smokers"	1	1	0	50
"1801"	"Waist-to-hip ratio adjusted for BMI x sex interaction"	8	7	1	53.3333333333333
"1802"	"Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)"	27	13	14	67.5
"1803"	"Waist-to-hip ratio adjusted for body mass index"	201	98	103	67.2240802675585
"1804"	"Waist circumference"	59	35	24	62.7659574468085
"1805"	"Waist Circumference - Triglycerides (WC-TG)"	2	0	2	100
"1806"	"Waist circumference adjusted for BMI (adjusted for smoking behaviour)"	51	30	21	62.962962962963
"1807"	"Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)"	48	27	21	64
"1808"	"Waist circumference adjusted for BMI in active individuals"	89	46	43	65.9259259259259
"1809"	"Waist circumference adjusted for BMI in inactive individuals"	7	3	4	70
"1810"	"Waist circumference adjusted for BMI in non-smokers"	38	25	13	60.3174603174603
"1811"	"Waist circumference adjusted for BMI in smokers"	2	0	2	100
"1812"	"Waist circumference adjusted for body mass index"	171	90	81	65.5172413793103
"1813"	"Waist circumference and related phenotypes"	1	1	0	50
"1814"	"Walking pace"	5	2	3	71.4285714285714
"1815"	"Warfarin maintenance dose"	2	2	0	50
"1816"	"Weight"	18	11	7	62.0689655172414
"1817"	"Well-being spectrum (multivariate analysis)"	10	6	4	62.5
"1818"	"White blood cell count"	140	82	58	63.0630630630631
"1819"	"White blood cell count (basophil)"	7	4	3	63.6363636363636
"1820"	"White blood cell count (eosinophil)"	2	1	1	66.6666666666667
"1821"	"White blood cell count (lymphocyte)"	1	1	0	50
"1822"	"White blood cell count (monocyte)"	4	2	2	66.6666666666667
"1823"	"White blood cell count (neutrophil)"	2	0	2	100
"1824"	"White blood cell types"	12	4	8	75
"1825"	"White coat effect (clinic systolic blood pressure minus ambulatory systolic blood pressure)"	1	1	0	50
"1826"	"White matter hyperintensities"	2	1	1	66.6666666666667
"1827"	"White matter hyperintensity burden"	4	3	1	57.1428571428571
"1828"	"White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy"	1	1	0	50
"1829"	"White matter lesion progression (adjusted for white matter lesion burden at baseline)"	1	1	0	50
"1830"	"Wilms tumor"	2	2	0	50
"1831"	"Word reading"	2	0	2	100
"1832"	"Word spelling"	2	0	2	100
"1833"	"Worry"	7	3	4	70
"1834"	"Worry too long after an embarrassing experience"	2	2	0	50
"1835"	"Youthful appearance (self-reported)"	10	5	5	66.6666666666667
"1836"	"Yu-Zhi constitution type in type 2 diabetes"	1	1	0	50
